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1. Introduction 
1.1. Pancreatic cancer 
1.1.1. Epidemiology 
 
In economically developed countries, cancer is the leading cause of death and 
the second leading cause in developing countries. Globally, about 337,000 
people are being diagnosed with pancreatic cancer yearly [1]. Among cancer, 
pancreatic cancer remains a very aggressive entity as - referring to statistics 
from the US - only 7 % of patients survive past 5 years and most die within the 
first year after diagnosis (Siegel et al., [2, 3]). Beneath the poor prognosis its 
incidence is quite high (about 49,000 patients estimated diagnosed in 2015, [2]) 
and constantly rising (53,670 in 2017, [3]). Both contribute to pancreatic cancer 
being the fourth-leading cause of cancer related deaths (all numbers refer to 
statistics from the United States). The minority of patients (9-10 %) presents in 
a resectable stage; 5-year survival rate among those patients is only 26 % [2]. 
Symptoms occur rarely in early stages, that is why more than 80 % of patients 
are diagnosed with locally advanced or metastatic disease, which are both 
unresectable. Unfortunately, unresectable disease is associated with an 
expected survival of 6 months [4, 5]. Constant increase in incidence is related 
to cigarette smoking, obesity and diabetes type II. Chronic inflammation and 
insulin resistance are major risk factors for the development of pancreatic 
cancer. Besides, advanced age, inherited familial cancer syndromes, 
Ashkenazi Jewish heritage and dietary factors raise the individual risk for the 
development of pancreatic cancer [1].  
1.1.2. Tumor Biology and Microenvironment 
 
Current research describes oncogenic transformation in the pancreas as a 
multistage process including activation of oncogenes and loss of tumor 
suppressor genes [5]. Mostly, activating mutation in the KRAS gene followed by 
a mutation in one or more of the tumor suppressor genes TP53, p16/CDKN2A 
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and SMAD4 leads to the development of pancreatic cancer [6]. Both activation 
of KRAS and loss of tumor suppressor gene function seem to be indispensable 
for the development of pancreatic cancer, as mice with a single point mutation 
in the KRAS oncogene only developed pancreatic preneoplastic lesions [7]. 
Microenvironment constitutes - besides the mostly late diagnosis - another 
important reason for the poor prognosis. Delivery of systemically administered 
chemotherapy is impaired as, due to the dense extracellular matrix, 
configuration of blood and lymphatic vessels in pancreatic cancer exhibits an 
abnormal structure which inhibits perfusion resulting in an impeded delivery of 
chemotherapeutic drugs [8]. Therefore, novel therapy options aim at over-
coming that barrier which seems to protect tumor cells [9]. Besides the 
unfavorable stromal matrix, pancreatic cancer exhibits a large amount of 
inflammatory cells within the tumor. Those inflammatory cells reinforce the 
protumorigenic surrounding. This long-term inflammation contributes to the 
development of pancreatic cancer [10]. Additionally, inflammatory cells are 
mostly immunosuppressive cells instead of cytotoxic T-cells [11]. The 
advantage of cytotoxic T-cells, especially regarding virotherapy, would be the 
immunotherapeutic effect on infected cancer cells which is an efficient way to 
raise potency of oncolytic virotherapy [5]. Concerning propensity to metastases, 
a mechanism called epithelial to mesenchymal transition (EMT) plays an 
important role. EMT is a mechanism, which is originally crucial for differentiation 
of tissues and organs in development and includes the loss of E-Cadherin. In a 
malign setting, EMT is associated with metastases and worse prognosis [12]. 
Especially for pancreatic cancer, EMT was shown to correlate with systemic 
aggressiveness and resistance towards chemotherapy [13]. 
1.1.3. Therapy 
 
As described above, resection is only an option in about 20 % of all cases, 
although systemic recurrence constitutes a major problem [14]. If pancreatic 
cancer is already locally advanced or metastatic, a palliative chemotherapy has 
been the only option so far. Since 1997, gemcitabine (Gemzar, Eli Lilly, 
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Indianapolis, IN), a nucleoside analogue was standard first-line therapeutic [15]. 
Therapy with gemcitabine leads to a 5-year survival of only 2 %, 1-year survival 
is between 17 and 23 % [15-17]. Add-on of further chemotherapeutic drugs was 
mostly inefficient and did not result in any benefit concerning progression-free 
survival or long-term survival. Two important exceptions to mention are a 
combination of gemcitabine with erlotinib, which targets an epidermal growth 
factor tyrosine kinase (TKI-EGFR) with an improvement of overall survival of 2 
weeks [16] and add-on of nab-paclitaxel (Abraxane®, Celgene) [18]. Nab-
paclitaxel, which was approved by the US FDA in 2013, consists of albumin-
bound paclitaxel, a microtubule inhibitor, and was reported to work 
synergistically with gemcitabine in a murine model [19]. In a multinational phase 
III study, nab-paclitaxel in combination with gemcitabine prolonged median 
overall survival significantly in patients with metastatic pancreatic cancer [20]. 
Another therapy regimen, which was established in 2011, constitutes a 
combination of three chemotherapeutic drugs and one adjuvant: FOLFIRINOX, 
including 5-fluorouracil plus leucovorin, irinotecan and oxaliplatin (FOL= 
Leucovorin Calcium (Folinic Acid); F = Fluorouracil; IRIN = Irinotecan 
Hydrochloride; OX = Oxaliplatin). However, this regimen is reserved for patients 
with good performance status, as the side effects are quite severe. Overall 
survival improved compared to gemcitabine alone about 4.3 months [17]. 
Expectedly, combination therapy with more than one chemotherapeutic agent 
led to more severe side effects, more precisely a greater risk for grade 3-4 
toxicities than gemcitabine alone [21]. 
 
1.2. Gemcitabine 
  
1.2.1. Chemotherapy with Gemcitabine 
 
Gemcitabine and its mode of action has been described first by Huang et al. in 
1991 [22]. In his work, Huang described the influence of 2',2'-difluoro-
deoxycytidine - which describes the chemical structure of gemcitabine - on 
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DNA-synthesis. Gemcitabine is an analogue of the nucleoside deoxycytidine, 
which explains its efficacy as antimetabolite. As gemcitabine is incorporated as 
‘wrong’ metabolite during DNA-synthesis, DNA-synthesis comes to a pause 
leading to cell death. Additionally, the enzyme ribonucleotide reductase (RNR), 
which is essential for DNA replication, is inhibited by one of the metabolites of 
gemcitabine [23, 24]. 
In the case of pancreatic cancer, gemcitabine has shown to be one of the most 
efficient chemotherapeutics as 1-year survival was about 18 % in comparison 
to therapy with 5-fluorouracil (5-FU), which led to a 1-year survival of only 2 % 
[25]. 
 
 
 
Figure 1: Metabolism and mechanisms of action of gemcitabine according to 
Shore et al. [24]. Incorporation of nucleotides into DNA leads to a pause of DNA 
synthesis and consequently to cell death. Inhibition of the enzyme ribonucleotide 
reductase leads to an inhibition of DNA polymerase.  
 
Figure: Shore et al.: Review article: Chemotherapy for pancreatic cancer. 
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1.2.2. Therapy induced senescence 
 
Gemcitabine is capable not only to kill cells but also to bring cells in a state, 
which can be compared to hibernation. This state is referred to as 
‘senescence’, which originates from the Latin verb ‘senescere’, which means 
‘aging’. Senescence has firstly been described in cell culture by Hayflick et al. 
in 1964 [26].    
Characterization of senescence includes a permanent growth arrest and a 
distinct cellular morphology [27]. Senescent cells appear flattened and 
enlarged, the cytoplasmic granularity is enhanced and the nucleus prominent. 
Moreover, senescent cells express senescence-associated β-galactosidase 
[28] as a correlative of increased lysosomal mass [29]. 
Senescence can be triggered by numerous mechanisms, including loss of 
telomeres or harboring of genetic damage, which both result in a DNA damage 
response (DDR), initiating senescence [30]. DDR itself reinforces senescence 
as it is linked to so-called DNA-SCARS (DNA segments with chromatin 
alterations reinforcing senescence). These are chromatin alterations, which 
lead to secretion of DDR proteins. Moreover, DDR leads to a distinct 
senescence associated secretory phenotype (SASP), including growth factors, 
proteases and cytokines [31, 32]. Thus, senescent cells still have paracrine and 
autocrine functions, although they are not able to replicate. 
 
 
1.3. Oncolytic Virotherapy 
 
1.3.1. History and development 
 
Oncolytic virotherapy (OV) has been detected “accidentally” as spontaneous 
tumor regression has been reported in the course of naturally occurring virus 
infections. The earliest reports go back to the late 19th century, mostly in 
leukemia or - more recently published - also in lymphoma. However, tumor 
regression was only short term, lasting 1 or 2 months [33-38]. Of note, those 
Introduction 
_______________________________________________________________ 
10 
findings were preferentially made in young patients with a suppressed immune 
system as they suffered from either leukemia or lymphoma [39]. In the 
beginning of the 20th century, ideas for the exploitation of viruses as cancer 
therapeutics arose; yet first important approaches, using for example Hepatitis 
B virus or Mumps virus were made starting in 1949 [40, 41]. The focus on 
patient’s safety was minor than nowadays, as viruses were not attenuated and 
unpurified body fluids were either injected or inhaled. Consequently, 
development of hepatitis, also leading to death, was among the side effects. 
After 1949, many different viruses have been tested preclinically and clinically – 
with a special focus on the Egypt 101 isolate of the West Nile Virus. In the 
course of those experiments, researchers found out about most disadvantages 
of OV: in patients with an intact immune system, viruses were often ineffective. 
If patients were immunosuppressed, as the malignancy involved the immune 
system, side effects were too severe if not life threatening or fatal [39, 42, 43]. 
The abandoning of those ineffective or unsafe viruses resulted in a 
convergence of interest towards more effective viruses for OV such as adeno-
viruses, herpesviruses, picornaviruses, paramyxoviruses and poxviruses. The 
named viruses were mostly used in an attenuated version due to the 
pathogenicity of wild type viruses. Besides human pathogenic viruses, which 
are either attenuated or quite mild concerning their symptoms, animal viruses 
without human pathogenicity were tested as OVs. One important example is 
the Newcastle Disease Virus, an avian virus [44], which continues to be used in 
cancer therapy with good remission rates [45]. In November 2005, a 
breakthrough in the field of OV was achieved: China was the first country to 
approve an OV for cancer therapy. A genetically engineered adenovirus called 
H101 was approved for the treatment of head and neck cancer [46]. In 2015, a 
engineered herpes simplex virus (T-VEC) has been approved for the treatment 
of malignant melanoma in the US and Europe [47, 48] 
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1.3.2. Mechanism of viral infection in tumors and oncolysis 
 
The main principle of oncolytic virotherapy is the exploitation of a natural 
phenomenon, as viruses are commonly parasites in infected cells. Some 
viruses exhibit a natural tropism for cancer cells – the mechanisms of such a 
tumor-selectivity are not always known. Concerning measles virus, viral entry is 
granted by an overexpression of the CD46 receptor in tumor tissues [49]. 
Defects in the IFN signaling pathway facilitate viral replication. Mostly, 
engineering is needed to grant tumor selectivity [50]. 
After infection, three steps are very important for effective operation of oncolytic 
virotherapy: (i) first of all, the direct cytotoxicity of viruses towards their host 
cells; host cell machinery is exploited until destruction to allow the virus to 
replicate; (ii) in the course of destruction, viral particles are released, which 
infect further tumor cells [50]; (iii) in a living organism, the immune system is 
activated by the stimulus of the viral infection. As the focus is within the infected 
tumor, the immune system will attack preferentially tumor cells and 
consequently, virus induces an immune response to the tumor [5]. Russel and 
Peng call the described mechanisms of OV “The oncolytic virotherapy 
paradigm” (Fig. 2) which provides a good review on the involved components. 
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Figure 2: The oncolytic virotherapy paradigm according to Russel and Peng [51]. 
For efficient OV, three components are indispensable. (i) Delivery of the virus to the 
tumor has to be granted. Therefore, virus must be targeted to tumor cells and 
overcome immunologic barriers. (ii) Killing of infected cells by viral toxicity. Viral 
replication within the tumor cells is critical to ensure further infection and spread of viral 
particles. (iii) As long-term effect, stimulation of the immune system is eligible. 
Remaining tumor cells are targeted leading to remission without relapse. 
 
 
 
 
1.3.2.1. Advantages and disadvantages 
 
As oncolytic virotherapeutics are rather different from other anticancer drugs, 
they include special advantages and disadvantages. The first unique feature of 
OVs is their ability to replicate. Thus, if infection and replication are efficient, an 
augmentation of the administered viral load is taking place [52]. Another 
advantage of that mechanism is the automatized ‘dose finding’. As only cancer 
cells allow viral particles to replicate, replication is self-limiting as soon as all 
cancer cells are lysed. Consequently, side effects are rather soft or missing, as 
the therapeutic is quite targeted and only cancer cells are affected. One 
important example to mention is the overexpression of CD46 in cancer cells, 
which leads to a facilitated viral entry of MeV [52]. The stimulation of the 
immune system enhances the therapeutic effect by targeting cancer cells, 
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which are under normal conditions capable to evade the immune system [53, 
54].  
Yet oncolytic virotherapy also meets obstacles. As mentioned above, the 
immune system plays an important role for virotherapeutical success. Never-
theless, the immune system is also the predominant obstacle to overcome [55]. 
To minimize side effects and to ensure that virotherapy is safe (see 1.3.1. 
History and development), only attenuated viruses or viruses with a low patho-
genicity are used for OV. Consequently, viruses are rarely challenging 
opponents for the immune system. In the worst case, viruses are detected and 
destroyed directly after application. Immunosuppression is not a definite 
solution for this problem – as symptoms of the viral infection are likely to get out 
of control. To overcome the neutralizing effect of the immune system towards 
administered viruses, different ways of application were investigated. Intra-
venous injection is quite disadvantageous if the immune system is familiar with 
the applied virus [56]. This precondition is common, as patients are either 
vaccinated (e.g. measles virus) or have been infected with the virus before.  
Another possibility – though not always easy to realize – is intratumoral 
application [57]. The advantage of this method is obviously the localized rather 
high concentration including the prevention of systemic side effects. For 
peritoneal carcinomatosis, intraperitoneal application is also under clinical 
investigation by our group as it targets not only primary tumor but also 
intraperitoneal dissemination [58]. In our phase I/II study we were able to show, 
that intraperitoneal application does not lead to severe side effects when a 
recombinant vaccinia virus was administered in patients with metastatic gastric 
cancer or ovarian cancer or mesothelioma. Tumor cells in ascites were shown 
to decrease in numbers by only a single dose of vaccinia virus. 
However, intratumoral and intraperitoneal application are limited as not every 
cancer entity can be reached by those methods. Moreover, one advantage of 
intravenous administration is, that not only the primary tumor is targeted but 
also possible metastases [59].  
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1.3.2.2. Enhancing oncolytic effects 
 
To improve oncolytic effects, the main goal is to overcome the obstacles 
described before. Simplified, that means to ensure delivery and replication of 
the virus and to stimulate the immune system for a ‘second hit’ of the tumor. 
The different ways of delivery have been described before; emphasizing that 
intravenous injection is the method of choice to grant delivery to all tumor sides 
and possible metastases. For that purpose, the immune system has to be 
‘compassed’.  
The main ‘enemies’ for successful delivery are (i) liver and spleen, where 
viruses are cleared by the mononuclear phagocytic system (MPS) and (ii) 
serum factors such as antibodies or complement, which neutralize viruses [59]. 
To minimize sequestration by liver and spleen, one option is to modify viral coat 
proteins to avoid opsonization and subsequent phagocytosis by the MPS [60]. 
Two modifications of the viral coat proteins for prolonged circulation time are 
polyethylene glycol (PEG) and N-(2-hydroxypropyl)methacrylamide (HPMA) 
[61, 62] which has been investigated for example for VSV [63] and adenovirus 
type 5 [64]. To evade neutralization by serum factors, an efficient way is to 
‘hide’ the virus inside of carrier cells such as tumor cells [65] or normal primary 
cells with the natural ability to home to tumor beds [66]. Of course, carrier cells 
should not be killed by the virus before the tumor has been reached [59]. 
Especially for mesenchymal stem cells (MSCs), dendritic cells and T cells 
investigations concerning delivery of the virus to the tumor are quite promising 
and constitute an interesting approach [67-69]. 
Further key points for successful delivery include optimal targeting of the tumor 
which means (i) tumor blood vessels must be permeable for virus and (ii) tumor 
vessel endothelium must be targeted by the virus itself [59]. 
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1.4. Measles Virus 
 
1.4.1. Introduction, Epidemiology and History 
 
Measles virus is a leading cause of death in children in developing countries, 
even though a cost-effective vaccine exists [70]. Measles is one of the most 
contagious diseases and transmitted by aerosols. Almost every infection 
becomes clinically manifest and can include severe complications; especially in 
developing countries, malnutrition raises lethality [71]. According to the WHO, 
in 2015 there were 134,200 measles deaths globally. Even though those 
numbers seem to be enormous, efforts to raise the vaccination coverage have 
led to a drop of measles deaths of 79 % worldwide between 2000 and 2015 
[70], after the WHO had launched a worldwide program to eliminate measles 
[71]. In 1954, John F. Enders and colleagues firstly isolated the virus in cell 
culture, followed by the development of the live attenuated measles vaccine in 
1963 [72]. 
 
1.4.2. Classification 
 
According to the International Committee on Taxonomy of Viruses (ICTV), 
measles virus belongs to the order mononegavirales, the family paramyxo-
viridae and the genus morbillivirus; measles virus is one of 7 species of the 
genus morbillivirus, like rinderpest or canine distemper virus [73]. 
 
1.4.3. Structure, Pathology and Infection 
 
As measles virus belongs to the Paramyxoviridae, it is a negative-stranded 
RNA-virus with an envelope [74]. The two envelope proteins are the hem-
agglutinin (H) and the fusion (F) protein, which are responsible for membrane 
attachment and cell fusion [72]. As depicted in Figure 3, the mentioned proteins 
are two of a total of six viral proteins (F, H, L, M, N, P), which are encoded in 
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the RNA genome [75]. The receptor protein on the host side for wild type virus 
is the signaling lymphocyte activation protein (SLAM / CD150), which is mainly 
expressed by immune cells, leading to lymphotropism and immune 
suppression. Measles vaccine strains use CD46 as a receptor. CD46 is 
ubiquitously expressed on human cells except for erythrocytes and frequently 
overexpressed on malignant cells [52, 72]. The interaction of the mentioned 
receptors with the envelope proteins leads to viral entry. Usually, virions are 
transmitted via aerosol droplets [72], leading to a primary infection of the 
respiratory tract [75]. The primary infection is either mediated by the receptor 
protein SLAM or a newly discovered epithelial receptor called Nectin-4, which is 
an adherence-junction protein. Nectin-4 can be found on polarized epithelial 
surfaces, including those of the airways and adenocarcinoma. Concerning 
oncolytic virotherapy, the manner of application (e.g. intravenous, intratumoral, 
intraperitoneal) influences primary infection, as there is no transmission via 
aerosol droplets. The CD46 receptor, which is overexpressed in malignant cells 
leads to a preferred infection within the tumor [52]. 
 
 
 
 
 
Figure 3. Schematic diagram 
of measles virion and 
genome 
(a) Depicted are the RNA 
genome and the six viral 
proteins (F, H, L, M, N, P). H 
and F are associated very 
closely within the envelope. 
(b) The RNA genome of MeV 
contains six genes and about 
16 kB. The function of the C 
and V proteins, which are non-
structural and encoded by the 
P gene, is not fully understood 
but related to interferon 
antagonism 
 
 
 
Figure: 
Yanagi et al.: Measles virus, 
cellular receptors, tropism and 
pathogenesis  
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1.4.4. Vaccination and use as OV 
 
In 1957, John F. Enders and Thomas C. Peebels described for the first time the 
isolation of measles virus. As the 11-year-old child, from whom they isolated 
the virus, was called David Edmonston, they called it “Edmonston strain” [76]. 
Having achieved that hallmark, the next logical consequence was the 
development of a vaccine. The isolated virus was attenuated by infection of 
chick embryo cells, leading to the license of the vaccine in 1965 [72]. Since 
then, the vaccine was used in more than a billion patients and has never 
happened to retrieve its former pathogenic abilities [77]. 
The safety and stability of the vaccine is a very important aspect concerning 
oncolytic virotherapy as the vaccine is used for virotherapeutic approaches. So 
far, the vaccines, which have been derived from the Edmonston vaccine strains 
are able to selectively infect, replicate within and lyse cancer cells without 
significantly harming benign ones [77]. 
Considerations concerning viruses as cancer therapeutics base upon 
numerous case reports, which describe cancer remission after viral infection 
(see chapter 1.3.1.). Concerning measles, Bluming and Ziegler described in 
1971 the case of an eight-year-old boy suffering from Burkitt’s lymphoma, who 
showed a remission after a natural measles infection [37]. 
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Figure 4. Remission of Burkitt’s Lymphoma after Measles Infection. 
The picture on the left was taken on the first of December in 1970 showing a swelling 
of the right eye socket, which was histologically diagnosed as a Burkitt’s lymphoma. 
After the picture was taken, the boy was infected by wild type measles, leading to a 
decline of the tumor (picture in the middle). The picture on the right was taken on the 
6th of January in 1971; no signs of tumor or measles exanthema are visible anymore. 
Taken from Bluming and Ziegler: Regression of Burkitt’s Lymphoma in association with 
Measles Infection [37]. 
 
 
In the following years, measles virus as oncolytic agent has been investigated 
more intensely. As the side effects of a measles infection can be quite severe 
and life-threatening [70], the opportunity of a safe vaccine with oncolytic 
potency as present in the case of measles is enormous. So far, measles 
vaccine virus has been shown to be efficient in various preclinical works [52, 
78], but also in vivo, for example when administered intraperitoneally in patients 
with ovarian cancer, the treatment with measles vaccine virus showed 
promising results [79]. Besides, measles vaccine virus is currently under 
investigation in patients suffering from recurrent glioblastoma multiforme and 
recurrent or refractory multiple myeloma [52].  
To improve therapeutic success, measles vaccine virus has been genetically 
engineered in different ways. In this study, a vaccine strain armed with a fusion 
protein consisting of cytosine deaminase (CD) and uracil phosphoribosyltrans-
ferase (UPRT), called Supercytosinedeaminase (SCD) was used (MeV-SCD). 
SCD catalyzes the deamination of cytosine to uracil [80], an enzymatic step, 
which is not performed in normal human cells [81]. For oncolytic purposes, the 
prodrug 5-fluorocytosine (5-FC) can be added, leading to severe cytotoxic 
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effects as the SCD fusion protein catalyzes the deamination to 5-FU [81]. The 
application of 5-FC and consequently the efficiency of arming measles virus 
with SCD is not subject of this work but has been investigated intensively by 
our group [82]. Other examples for engineered measles vaccine viruses are 
focus on the usage of tracers to visualize infection. In this work, MeV-GFP, 
encoding a green fluorescent protein, has been used to depict infection. In 
clinical studies, tracers are used to monitor infection and cancer progress or 
remission and to administer additional radiation very precisely. For example, 
sodium iodide symporter gene leads to a facilitated localization and offers the 
opportunity for tumor radiovirotherapy [79].  
Another possibility that can be employed to amplify the efficiency of oncolytic 
virotherapy is the induction of anticancer immunity. Immunologic effects can 
theoretically be achieved by every oncolytic therapy approach, as the infection 
leads to local inflammation, activating the immune system [83]. To enhance that 
effect, viruses can be armed with granulocyte-macrophage colony-stimulating 
factor (GM-CSF), for example, leading to immune cell recruitment, going along 
with clinical benefits [57, 84]. 
Even though all those important hallmarks have been achieved, primary 
resistance phenomena of cancer cells towards measles virus are still an 
obstacle to overcome. Analyzing the NCI-60 tumor cell panel, only 50 % of all 
cell lines are susceptible towards MeV-SCD [78]. Our group was able to show, 
that primary resistances could be resolved either by increasing the multiplicity 
of infection (MOI) of MeV-SCD or combining MeV-SCD with 5-FC, exploiting 
the SCD suicide gene function [78]. 
To accomplish this work, further combinatorial options have to be investigated 
to overcome resistance phenomena, for example tumor-specific chemotherapy 
as depicted in this work. 
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1.5. Preexisting findings for virotherapeutic 
approaches in combination with gemcitabine 
 
As a background for our work, there are two elementary publications to 
mention, dealing with oncolytic virotherapy in combination with gemcitabine or 
senescence. In both works, measles vaccine virus was used as oncolytic agent. 
Table 1 sums up the work of Bossow et al. [85], investigating the susceptibility 
of gemcitabine-resistant pancreatic cancer cell lines towards measles vaccine 
virus infection. Facilitated, the results show, that there is no difference in 
gemcitabine-resistant pancreatic cancer cell lines and naïve ones concerning 
infection of measles vaccine virus, cell viability and prodrug activation (as an 
armed virus was used). For translation into clinical practice, those findings are 
rather important, as resistances of pancreatic cancer cell lines towards 
chemotherapy are a major obstacle to overcome. 
  
 
cell line 
all gemcitabine-
resistant, incubated 
> 200 d, n=nM 
gemcitabine 
BxPC-3/ 
Gmc-100 
Capan-1/ 
Gmc-50 
T3M4/ 
Gmc-100 
Mia PaCa-2 / 
Gmc-25 
comparison with 
naive cell line 
BxPC-3 Capan-1 T3M4 Mia PaCa-2 
susceptibility to 
MeV-infection: 
formation of 
syncytia 
 
= 
 
= 
 
= 
 
= 
susceptibility to 
MeV-infection:    
cell viability 
 
= 
 
= 
 
= 
 
= 
efficacy of 
bystander killing 
by the prodrug 
fludarabine 
 
= 
 
= 
 
= 
 
= 
 
Table 1. Summary of the results of Bossow et al. “Armed and targeted measles 
virus for chemovirotherapy of pancreatic cancer“ (facilitated) investigation of four 
pancreatic cancer cell lines showed, that a resistance towards chemotherapy 
(gemcitabine) does not influence susceptibility towards a MeV infection. The virus in 
this work was armed with a prodrug convertase purine nucleotide phosphorylase, 
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promoting the prodrug fludarabine. Efficacy of the prodrug was not impaired by 
gemcitabine-resistance of the cell lines. 
 
 
 
Weiland et al. [27] were able to show that senescent cancer cells are more 
efficiently infected and lysed than there non-senescent counterparts. Table 2 
provides a facilitated summary of the findings in the publication: senescence 
was induced using several agents (doxorubicin, taxol, gemcitabine) in cancer 
cell lines originating from different organs (hepatoblastoma, mammary gland, 
pancreas). In comparison to non-senescent cancer cells of the same kind, 
oncolysis was more efficient in senescent cell lines, demonstrated by reduced 
cell mass in the SRB assay. As explanation for that phenomenon, CD-46 
upregulation and interferon-beta release were investigated in the senescent 
cells. So far, no pattern for the described findings could be detected. 
 
cell line 
(all human origin) 
results 
 
HepG2 
Hepatoblastoma 
(Senescence induced by 
doxorubicine, taxol, 
gemcitabine) 
MCF7 
Mammary gland 
(Senescence induced 
by taxol) 
MIA PaCa-2 
Pancreatic  
(Senescence induced 
by gemcitabine) 
Reduced cell mass 
(SRB)* + + + 
Senescent cellular 
phenotype +   
GFP-expression 
(ubiquitous) +   
Formation of syncytia +   
Increased viral titers* +   
Accelerated cell lysis* +   
CD-46 upregulation* -   
Interferon-beta 
release° ø  (+/-) 
* in comparison to each treatment (senescence-inducing chemotherapeutic drug or MeV-infection) alone 
° Senescence induced by gemcitabine in all three cell lines; IFN-beta release measured after viral 
infection  
 
Table 2. Summary of the results of Weiland et al. “Enhanced killing of therapy-
induced senescent tumor cells by oncolytic measles vaccine viruses” The results 
show, that MeV-infection and oncolysis is more efficient in senescent cells than in 
untreated cancer cells. For HepG2, further dimensions of viral infection such as GFP-
expression (a recombinant MeV carrying green fluorescent marker protein was used), 
formation of syncytia and viral titers have been investigated. As likely explanations for 
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either a facilitated viral entry caused by CD-46 upregulation or an increased viral 
replication caused by decreased interferon-beta release as a result of senescence-
inducing drugs are to be mentioned. No general pattern for those two factors as reason 
for facilitated viral entry or increased viral replication could be detected in the 
mentioned cell lines.  
 
1.6. Objective 
 
Due to the poor prognosis of patients who suffer from pancreatic cancer, it is 
very important to overcome therapy resistance. Gemcitabine is known to be 
effective in pancreatic cancer; however, it only is capable to delay tumor 
progression for a few weeks. Dose-dependent side effects limit the application 
additionally. Therefore, it is necessary to counteract pancreatic cancer on 
another target to make therapy with gemcitabine more efficient and to reduce 
the dosage being required.  
Measles vaccine virus (MeV) has shown to replicate within pancreatic cancer 
cells and to have a lytic potential. Thus, it seemed a convenient therapeutic to 
combine MeV with gemcitabine. The question coming up with this approach is 
the mutual influence of each therapeutic on the other and the joint effect. As 
MeV usually replicates in pancreatic cancer and gemcitabine induces 
senescence, it was important to find out, whether either of these two effects 
was influenced in the combinatorial context.  
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2. Material and Methods 
 
2.1. Material 
 
2.1.1. Consumables 
 
Cell scrapers     Corning Inc. 
Combitips 2.5 ml, 12.5 ml    Eppendorf 
Conical-bottom tube 5 ml    BD Falcon 
Conical-bottom tube 15 ml    Greiner Bio One 
Conical-bottom tube 50 ml    BD Falcon 
Cryotubes 1 ml     Corning Inc. 
Pasteur pipettes, 230 mm long size  WU Mainz 
Pipettes 5 ml, 10 ml, 25 ml, 50 ml  Corning Inc. 
Pipette tips 100 µl, 200 µl, 1000 µl               Biozym / Peqlab 
Reaction tubes 1.5 ml, 2.0 ml   Eppendorf 
Reaction tubes 1.5 ml, 2.0 ml (amber)    Eppendorf 
Tissue culture flask 75 cm², 150 cm²  Greiner Bio One 
Tissue culture plate 6 well    Corning Inc. 
Tissue culture plate 12 well   Corning Inc. 
Tissue culture plate 24 well   TPP 
Tissue culture plate 96 well   TPP / Corning Inc. 
 
2.1.2. Chemicals 
 
β-Galactosidase Reporter Gene Staining Kit    SIGMA 
 
5-Fluorouracil     Pharmaceutical Department,  
       Universitätsklinikum Tübingen 
Acetic Acid      Merck 
Descosept       Dr. Schuhmacher GmbH 
DMSO      AppliChem  
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Erlotinib      Roche 
Gemcitabine      LC laboratories 
Hydrochloric Acid     S3 Chemicals 
Irinotecan      Fresenius Kabi 
Isopropanol (70%)     SAV Liquid Production 
Nab-Paclitaxel     Celgene 
Oxaliplatin      Fresenius Kabi 
Paraformaldehyde (PFA), 4.0 %   Otto Fischar GmbH 
Secusept      ECOLAB 
Sulforhodamine B     Sigma Aldrich 
Thyazolyl BlueTetrazolium Bromide   Sigma Aldrich  
(MTT staining) 
Trichloroacetic acid     Carl Roth 
TRIS       Carl Roth 
Trypan blue      SIGMA 
 
2.1.3. Antibodies 
 
Alexa Fluor® 546      Invitrogen 
Goat Anti Mouse IgG (H+L), A11003  Thermo Fisher Scientific 
anti-MeV-NP      Creative Biolabs 
 
2.1.4. Media, Sera and Buffer 
 
DMEM      BIOCHROME 
DMEM (colorless)     BIOCHROME 
EDTA Trypsin     Lonza 
Fetal Bovine Serum    Gibco 
Opti-MEM      Gibco / Life Technologies 
PBS (cell culture use)    PAA 
Tween-20       Carl Roth 
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Self-prepared solutions: 
 
MTT staining solution              MTT   2.5 g / ml  
                 Colorless DMEM 
 
MTT solvent      HCl (fuming) 10 ml 
       Isopropanol 90 ml 
 
PBS (non cell culture use)    NaCl    137 mM (8 g) 
       KCl  2.7 mM (0.2 g) 
       Na2HPO4 10 mM (1.44 g) 
       KH2PO4 1.8 mM (0.24 g) 
       H2Odd filled up to 1 l 
 
SRB dye (0.4 % in 1 % acetic acid)  SRB  4 g 
       Acetic acid 10 ml 
       H2Odd filled up to 1 l 
  
10 x TBS (Tris-buffered saline)   NaCl  1.5 M (438.3 g) 
       TRIS  0.5 M (302.85 g) 
       pH      7.4, adjusted with  
         HCl 
       H2Odd  filled up to 5 l 
 
TBS-Tween (0.02 %)    Tween-20  5 ml of 20 % 
       10 x TBS 500 ml 
       H2Odd filled up to 5 l 
 
TCA solution (10 %)    TCA  100 g 
       H2Odd filled up to 1 l 
 
TRIS base      TRIS  10 mM (1.21 g) 
       H2Odd filled up to 1 l 
pH  10.5 
 
2.1.5. Cell lines 
 
BxPC-3, MIA PaCa-2, PANC-1, Vero  German Collection of Micro-
organisms and Cell Cultures (DSMZ, 
Braunschweig, Germany) 
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2.1.6. Virus 
 
MeV-GFP   Wolfgang Neubert 
MeV-SCD Wolfgang Neubert 
2.1.7. Laboratory Equipment 
 
 
Autoclave 3850 EL Systec 
Centrifuge Eppendorf, Heraeus 
Fluorescence microscope Olympus 
Haemocytometer Hecht Assistant 
HPLC Merck Hitachi 
lncubator Heraeus / Integra / Memmert 
Laminar Flow Work Bench Heraeus  
Light microscope Olympus 
Multichannel pipette Eppendorf 
Handystep Brand  
Photometer Genios Plus  Tecan 
Pipette Boy Integra  
Pipettes BioHit / Eppendorf  
Refrigerator (-18 °C, -80 °C, -120 °C) Liebherr  
Rotational Vacuum Concentrator Christ 
Vortexer  Janke + Kunkel IKA Labortechnik 
Water bath 3042 (37 °C) Köttermann 
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2.2. Methods 
 
2.2.1. Cell culture 
 
2.2.1.1. General cell culture 
 
All cell lines were kept in Tissue culture flasks with vented caps and cultured in 
DMEM supplemented with 10% FBS. Flasks and plates were stored in an 
incubator at 37 °C in a humidified atmosphere containing 5 % CO2. Treatment 
was performed under sterile conditions in a laminar flow workbench. When 
reaching confluence, cells were washed once with sterile PBS (37 °C) and 
removed from culture vessel with trypsin/EDTA. After removal, cells were 
diluted in fresh medium and seeded partly in new flasks and partly on tissue 
culture plates. 
 
2.2.1.2. Determination of cell number in solution 
 
Before seeding cells on tissue culture plates, the number of cells was 
determined using an improved Neubauer haemocytometer. The counting 
chamber of the improved Neubauer haemocytometer is divided into squares, 
which are divided in 16 smaller squares to facilitate counting. One large square 
measures 1 mm² and the distance between the counting chamber and the 
cover glass is 0.1 mm. Thus, the volume contained by one square is 100 nl. 
Cells in 4 squares were counted and the average of 4 squares was multiplied 
with 10,000, which produces the number of cells per ml. To discriminate dead 
cells from living ones, cells were diluted in trypan blue. Trypan blue only stains 
dead cells, which effects that living cells are brighter than the surrounding. The 
thinning caused by the trypan blue solution was considered in calculation. 
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2.2.1.3. Cryopreservation of cells 
 
For long-term storage, cells had to be frozen at -80 °C. To isolate cells from 
medium, cell suspension was centrifuged at 1200 rounds per minute for 3 
minutes at room temperature. Afterwards, medium was removed and cells were 
re-suspended in cryo medium (DMEM with 20% FBS and 10% DMSO) to a 
concentration of circa 1000 000 cells per ml. 1 ml of the suspension was 
pipetted in cryo tubes which were put into a cryo freezing container and frozen 
slowly over night at -80 °C. 
To re-cultivate the cells, the cryo tubes were thawed in a 37 °C water bath in 
order to fasten the process and immediately diluted with DMEM containing 10% 
FBS. To remove DMSO, the cell suspension was centrifuged as described 
above and diluted in new medium. Cell suspension was cultivated in a cell 
culture flask. 
 
2.2.2. Cell viability assays 
 
2.2.2.1. Determination of cell mass / sulforhodamine b assay 
 
To quantify the remaining tumor cell mass after treatment with chemo-
therapeutics and/or MeV, a sulforhodamine b assay (SRB assay) was 
performed [86].  
Cells were seeded on 24 well plates at a cell number of 40 000 cells per well. 
After seeding the cells, plates were panned to spread cells evenly within one 
well. Afterwards, cells were incubated overnight to allow them to adhere. The 
next day, the actual experiment including either chemotherapeutics or MeV or 
both was performed. After a defined incubation time, cells were washed with 
500 µl cold PBS and afterwards fixed with 250 µl cold trichloroacetic acid (TCA, 
10 % w/v). After 30 minutes incubation at 8 °C, TCA was removed and plates 
were washed twice with tab water. Plates were dried overnight in a heating 
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cabinet (40 °C). To stain the fixed cells, plates were stained with 250 µl / well 
SRB staining solution. After an incubation time of 30 minutes, SRB staining 
solution was removed and cells were washed with 1% acidic acid until all 
unbound solution was removed. The plates were again dried in a heating 
cabinet and stored in dark until measurement (not longer than one week). For 
measurement, the stain was solubilized in tris (10 mM, pH 10). For average 
color intensity, 1 ml tris per well was chosen; if the stain was very intensive due 
to a high number of cells, the amount of tris was raised to 1.5 ml per well. After 
SRB was solubilized, 80 µl of the solution was transferred twice in a 96 well 
plate. Optical density was measured at a wave length of 550 nm in a micro titer 
plate reader. Density results of treated cells were related to the results of mock-
treated cells. 
 
2.2.2.2. Determination of cellular enzyme activity / MTT assay 
 
To review the accurateness of the SRB assay, another assay called MTT assay 
was performed. The difference in comparison to the SRB-Assay is that MTT 
assay measures the activity of cellular enzymes, thus the activity of living cells.  
The substance used in MTT assay is the yellow-colored tetrazole (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide which is reduced to 
formacan (purple color) by living cells [87].  
Seeding of cells and experiment were performed as described above. 
Before staining, cells were washed with warm PBS (500 µl per well). After that, 
cells were stained with 250 µl per well MTT staining solution. After the staining 
solution was added, plates were incubated at 37 °C for 2 hours. After 
incubation time, the staining solution was removed and plates were frozen at  -
20 °C. 
For measurement, the stained cells were solubilized in MTT solvent. 200 µl of 
the solution of each well was transferred in a 96 well plate and optical density 
was measured at a wave length of 570 nm and 650 nm in a micro plate reader. 
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2.2.3. Virological methods 
 
2.2.3.1. Virus infection 
 
To infect the cells with MeV-SCD, opti-MEM was used as Medium. Infection 
was performed after washing the cells with warm PBS. To infect 24 well plates, 
250 µl medium was added per well, in 6 well plates 1 ml. To make sure that the 
virus was able to infect, plates were panned every 15 to 20 minutes during 3 
hours of incubation time. After 3 hours, medium was changed and DMEM 
containing 10 % FBS or 5 % FBS (in the case of a virus growth curve) was 
added. When treated additionally with chemotherapeutics, the drugs were 
added when medium was changed. 
 
2.2.3.2. Virus growth curves 
 
To determine the influence of chemotherapeutics on virus growth, it was 
necessary to generate virus growth curves. Virus replication in cells was 
compared between cells, which were treated with chemotherapeutics and cells, 
which were not. Cells were seeded one day before infection on a six well plate. 
The number of cells seeded per well was 1 x 104. As first step, cells were 
infected with MeV-SCD as described above. As reference, one well per plate 
remained uninfected. After 3 hours, medium was removed and cells were 
washed three times with warm PBS. After that, 1 ml DMEM containing 5 % FBS 
and either chemotherapeutic or not was added on each well. The supernatant 
of one well per plate was removed and frozen at -80 °C in a test tube. 1 ml 
Opti-MEM was added on the same well and cells were scraped into the 
medium. Medium and contained cells were also frozen at -80 °C. Removal of 
supernatant and scraping of cells was repeated every 24 hours post infection 
(hpi) until 96 hours hpi. Harvested wells and space between the wells were 
filled with PBS to avoid drying of the plates. 
When all wells had been harvested, titration was started. One day before the 
start of titration, Vero cells (kidney epithelial cells extracted from an African 
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green monkey) were plated in 96 well plates. The cell number in each well was 
10 000, diluted in 200 µl DMEM + 5 % FBS. When Vero cells had attached to 
the culture dish and looked healthy the next day, titration could be started. 
 
For titration, samples were thawed in a 37 °C water bath for 2 minutes, 
vortexed for 15 seconds and centrifuged in a table top centrifuge at 3000 
rounds per minute (rpm) for 2 minutes. 
For serial dilution of the samples, a 96 well plate was used. For one sample, 
eight degrees of dilution were provided. The first well of a 96 well plate was left 
empty, the following 7 wells were filled with 270 µl DMEM + 5 % FBS. 300 µl of 
the supernatant of a centrifuged sample was then added into the first well. 30 µl 
of the first well was pipetted into the second well and re-suspended several 
times. This step was repeated from the second to the third well and so on using 
a new pipet tip for each well. 50 µl of each degree of dilution were then trans-
ferred to the Vero cells. The transfer step was repeated another three times to 
improve accurateness. 
The read out was performed after an incubation time of 96 hours. Before 
fixation and staining, plates were examined microscopically to detect signs of 
viral infection. When at least one syncytium could be found in a well it was 
considered as positive for viral infection. To make sure that all infected wells 
were stained, the following three wells of a positive one in the serial dilution 
were included in staining. After examination, medium was removed and plates 
were washed with 200 µl PBS per well. Then, cells were fixed with 50 µl of 4% 
formaldehyde and incubated for 10 minutes at room temperature. After fixation 
washing was repeated two more times. Plates can be stored with PBS at 4 °C 
for several days. 
To stain cells with antibodies and detect viral spread via immunofluorescence, 
samples were blocked for 30 minutes with TBS-Tween containing 1% FBS. Cell 
membranes were permeabilized by tween-20, which is contained in TBS-tween. 
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The permeabilization is necessary to enable antibodies to bind also to 
intracellular proteins. 
After blocking, the solution was replaced by the primary antibody (anti-MeV-NP; 
1:1000 in TBS-tween), which was allowed to incubate for 30 minutes. To 
remove free antibody, plates were washed three times with TBS-tween and 
afterwards, the secondary antibody (goat anti-mouse; 1:1000 in TBS-tween) 
was applied. Plates were incubated for another 30 minutes in the darkness to 
preserve the fluorescence. After incubation, plates were washed another three 
times with TBS-Tween. PBS was added in each well for storage and micro-
scopy. 
 
2.2.4. Senescence 
 
2.2.4.1. Detection of Senescence / senescence-associated β-
galactosidase activity (SA-β-gal) 
 
Gemcitabine is known to induce senescence, which is defined as an 
irreversible cell cycle arrest in cancer cells such as HepG2 (human hepato-
blastoma), MIA PaCa-2 and MCF7 (human mammary gland adenocarcinoma). 
This phenomenon has been investigated in combination with MeV by our group 
[27]. To find out, whether gemcitabine induces senescence in the 
concentrations used in this work and in combination with MeV-infected cells, a 
senescence assay was performed.  
MIA PaCa-2 was the cell line used for this assay. To facilitate counting of cells, 
cell number seeded per well was decreased to 2 x 104 cells per well in a six 
well plate. Infection with MeV-SCD and treatment with gemcitabine were 
performed analogical to the experiments described to determine cell viability to 
make results comparable. For infection, 1 ml Opti-MEM was added and 
incubated for three hours. After infection, medium was removed and replaced 
by 2 ml DMEM containing gemcitabine. To obtain a positive control, one well 
per plate remained uninfected and was treated with 100 µM gemcitabine. The 
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negative control was represented by a MOCK treated well. After an incubation 
time of 72 hours, plates were washed two times with 2 ml PBS per well. For 
fixation and staining, a staining kit (Sigma Aldrich) was used. After washing, 1.5 
ml fixation buffer was added on each well and incubated for 10 minutes at room 
temperature. After fixation, plates were washed another three times with PBS. 
Then, 1 ml staining solution was added in each well. Plates with staining 
solution were incubated for 12 to 16 hours at 37 °C in a carbon dioxide 
depleted atmosphere. Incubation time was considered adequate, when the 
majority of cells of the positive control were stained blue and the cells of the 
negative control remained unstained. Staining solution was removed and plates 
were washed two times with PBS. To store and count cells, 1 ml glycerol in 
distilled water was added.  
 
2.2.5. Microscopy 
 
Cells were continuously examined under the microscope to guarantee sterile 
and proper conditions. Therefore, the phase contrast microscope CK40 from 
Olympus was used. If any fluorescence had to be detected, the fluorescence 
microscope IX50 from Olympus was used. 
 
2.2.6. Safety 
 
The laboratory where the experiments of this thesis were performed is 
classified as Biosafety Level 2 of the Directive 2000/54/EC – biological agents 
at work from the European Parliament from the year 2000. Therefore, all 
experiments containing hazardous or potentially hazardous substances were 
performed under a laminar flow workbench. All materials were disinfected 
afterwards, irradiated with UV-light for at least 15 minutes and autoclaved. 
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2.2.7. Software 
 
For calculations, Microsoft Excel 2003 was used. Data was analyzed and 
pictured by Graph Pad Prism 4.0. 
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3. Results 
 
The aim of this thesis was to investigate the mutual influence between measles 
vaccine virus (MeV-SCD) and chemotherapeutic compounds (such as 
gemcitabine) on pancreatic cancer cell lines when administered simultaneously. 
Thus, it first was necessary to find out, how cellular growth was inhibited by 
both substances in comparison to treatment with one substance alone. In this 
context, two different cell viability assays were performed to determine either 
remaining tumor cell masses (by the SRB assay) or remaining activities of 
cellular enzymes (by the MTT assay). Another interesting issue was the 
influence of gemcitabine on viral replication. Hence, virus growth curves were 
generated to compare viral replication in pancreatic cancer cell lines infected 
with MeV-SCD alone or in combination with gemcitabine. As gemcitabine is a 
strong inductor of senescence, an irreversible cell cycle arrest, it was important 
to figure out, whether the infection of cells with MeV-SCD had an influence on 
that phenomenon. Therefore, a senescence assay (senescence-associated β-
galactosidase, SA-β-Gal assay) was performed. To illustrate contemporaneous 
presence of senescence and viral infection in the same cell, pictures of MeV 
infected and SA-β-Gal positive cells were taken.  
 
3.1. Introductory experiments 
3.1.1. Sensibility of pancreatic cancer cell lines for MeV-SCD 
and chemotherapeutic drugs 
 
As first step, pancreatic cancer cell lines MIA PaCa-2, PANC-1 and BxPC-3 
were treated with five different multiplicities of infection (MOI) of MeV-SCD 
ranging between 0.001 and 10 and incubated for 72 hours to investigate 
sensibility of cell lines to MeV-mediated cytotoxicity (Fig. 5, upper panels). Cell 
viability was determined by the SRB assay. It was necessary to determine a 
distinct MOI for each cell line, which showed an oncolytic effect but did not 
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reduce the tumor cell mass by more than 50 %. For the tumor cell line MIA 
PaCa-2, an MOI of 0.1 was the lowest concentration tested that revealed an 
oncolytic effect of about 10 %. Remaining cell viability for an MOI of 1 was 
about 25 %. In PANC-1, an MOI of 0.01 exhibited a slight oncolytic effect; cell 
viability for an MOI of 0.1 was about 40 %. In BxPC-3, an MOI of 0.1 resulted in 
a cell viability of about 75 %. Approaching an MOI with an oncolytic activity that 
did not undercut 50 % cell viability for each individual tumor cell line, the 
previous data were important to find a frame for experiments with further MOIs.  
The same applied for chemotherapy concentrations. Tumor cell sensibilities 
were tested for different concentrations of various chemotherapeutic drugs (Fig. 
5) including gemcitabine (0.01 µM – 100 µM), 5-Fluorouracil (5-FU, 0.001 mM – 
10 mM), oxaliplatin (0.01 µM – 100 µM), irinotecan (0.01 µM – 100 µM), nab-
paclitaxel (0.0001 – 100 µM) and erlotinib (0.01 µM – 100 µM). Incubation time 
of 72 hours (pink bars) was compared with incubation time of 48 hours (black 
bars). Gemcitabine and 5-FU revealed a significantly lower efficiency when 
incubation time was 48 hours in all tested cell lines. The same pattern was 
detectable for nab-paclitaxel but not as explicit as for the first two. In MIA PaCa-
2 and BxPC-3 cells, no difference in cytotoxicity between incubation times of 48 
and 72 hours for oxaliplatin and irinotecan could be found. In PANC-1, an 
incubation time of 72 hours showed a significantly higher cytotoxicity than 48 
hours. Erlotinib did not cause cell death in the used concentrations in PANC-1 
at all, whereas an effect was detectable in the other two cell lines beginning at 
10 µM. As an incubation time of 72 hours revealed a significantly higher 
cytotoxicity for chemotherapeutics in most cell lines, 72 hours were chosen as 
incubation time for the following experiments. Thus, it was nearby to administer 
MeV-SCD and chemotherapy as contemporaneously as possible. As described 
in 2.2.3.1., virus infection had to be performed in a different medium (opti-
mem), which was changed three hours post infection (hpi) and replaced by 
normal medium. Therefore, the best way to converge incubation time of MeV-
SCD and chemotherapy was to administer chemotherapy simultaneously with 
the change of medium 3 hpi (Figure 8A, scheme for experiments combining 
MeV-SCD with gemcitabine).  
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Figure 5. Upper panels (Figure and corresponding description published in [88]): 
“Susceptibility of pancreatic cancer cell lines to MeV-mediated oncolysis. Cells 
were infected with oncolytic measles vaccine virus MeV-SCD at the indicated MOIs. At 
72 h post infection the remaining cell masses were determined by Sulforhodamin B 
viability assays; 50% threshold is marked by a dotted line. Data are presented as the 
mean ± standard deviation of three independent experiments. MeV, measles vaccine 
virus, MOIs, multiplicities of infection.” Lower panels: Susceptibility of pancreatic 
cancer cell lines for chemotherapeutic drugs. Incubation time was either 72 hours 
(pink bars) or 48 hours (black bars) for chemotherapeutic drugs. Mean and standard 
deviation of three independent experiments are shown. Cell viability was measured 
using an SRB assay and normalized to a MOCK-treated control (MOCK = 100 %). 
 
3.1.2. Chemotherapeutic drugs suitable for combination with 
MeV-SCD 
 
Subsequently, distinct chemotherapeutics were chosen for testing in 
combination with MeV-SCD.  
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As the efficacy of erlotinib was either rather low in the concentrations used for 
the cell lines MIA PaCa-2 and BxPC-3 or non existing for the cell line PANC-1, 
no further combinatorial experiments with erlotinib were performed.  
The same applied for irinotecan and oxaliplatin as there were too high 
meanderings concerning sensibility for those chemotherapeutics between the 
three cell lines.  
Nab-paclitaxel revealed some issues concerning drug quality. Results were 
hard to reproduce, which was also illustrated by large error bars, as depicted in 
Figure 5. Approved therapeutic regimens for the mentioned chemotherapeutic 
compounds are mostly multidrug therapies consisting of distinguished 
combinations of the mentioned compounds – those regimens have not been 
investigated in this work, which may have an impact on the described results.  
As a result of this selection process, chemotherapeutic drugs chosen for 
combination experiments were gemcitabine and 5-FU. 
3.1.3. Identification of required multiplicities of infection of 
MeV-SCD and chemotherapy concentrations 
 
For combination experiments, it was necessary to investigate different MOIs of 
MeV-SCD in combination with different gemcitabine and 5-FU concentrations, 
which were within a rather small range as very low concentrations were used 
and it was indispensable to reach a certain cytotoxic effect. Cell viability was 
determined using the SRB assay.  
Accordingly, three MOIs of MeV-SCD and three different gemcitabine / 5-FU 
concentrations within a small range (table 3 for gemcitabine and table 4 for 5-
FU) were combined bailing out all 9 possibilities for combination settings (Fig. 6 
for gemcitabine and Fig. 7 for 5-FU). In the case of gemcitabine, the final MOIs 
/ concentrations were chosen looking for an only moderately cytotoxic effect 
when used as a single agent and highlighted within the table / figure (adjusted 
to remnant tumor cell viabilities between 50 and 80 %).  
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3.1.3.1. Gemcitabine and MeV-SCD in combination 
 
In MIA PaCa-2, the lowest concentration of gemcitabine (0.02 µM) was not 
efficient enough to undercut 50 % cell viability when combined with MeV-SCD. 
However, the highest concentration (0.04 µM) already caused cytotoxicity 
higher than 50 % when applied alone and was consequently too high for 
combination experiments. Gemcitabine concentration of 0.03 µM resulted in a 
cell viability of about 65 % when applied as a single agent and less than 50 % 
when combined with MeV-SCD for all used MOIs. The chosen MOI was 0.4 
(Fig. 6). In PANC-1, all listed concentrations of gemcitabine and all MOIs of 
MeV-SCD resulted in a cell viability of higher than 50 % when used alone and 
lower than 50 % when used in combination. Chosen concentration for further 
experiments was 0.075 µM gemcitabine and an MOI of 0.075 (Fig. 6). In BxPC-
3 only a gemcitabine concentration of 0.02 µM was low enough and did not 
undercut 50 % when used alone. In combination with MeV-SCD, remaining cell 
mass was less than 50 % for combination therapy for all MOIs. The MOI for 
further experiments was 0.125 (Fig. 6). 
Cell line 
MeV-SCD 
(MOI) 
gemcitabine  
(µM) 
MIA PaCa-2 
0.3 0.02 
0.35 0.03 
0.4 0.04 
PANC-1 
0.05 0.025 
0.075 0.05 
0.1 0.075 
BxPC-3 
0.075 0.02 
0.1 0.03 
0.125 0.04 
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Table 3. Listing of all MOIs of MeV-SCD and all concentrations of gemcitabine 
investigated to find the accurate dose for combination treatment. Every MOI of 
MeV-SCD was combined with every concentration of gemcitabine, resulting in nine 
possibilities for combination in each cell line. Colored concentrations denominate 
concentrations used for further experiments. For results see Figure 6. 
 
A. MIA PaCa-2 
MOI 0.02 µM gemcitabine 0.03 µM gemcitabine 0.04 µM gemcitabine 
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B. PANC-1 
MOI 0.025 µM gemcitabine 0.05 µM gemcitabine 0.075 µM gemcitabine 
0.05 
 
  
0.075 
   
0.1 
   
 
C. BxPC-3 
MOI 0.02 µM gemcitabine 0.03 µM gemcitabine 0.04 µM gemcitabine 
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0.1 
   
0.125 
   
Figure 6. Preliminary experiments investigating the efficacy of the combination 
of MeV-SCD and gemcitabine for each cell line (A = MIA PaCa-2, B = PANC-1, C = 
BxPC-3). Three individual MOIs of MeV-SCD and three concentrations of gemcitabine 
were combined (Table 3), resulting in nine graphs for each cell line. The MOIs / 
concentrations for each cell line were chosen looking for a moderate cytotoxic effect 
when used as a single agent (aiming at tumor cell viabilities in the range of 50-80 %). 
The best fitting combination of both (indicated by colored graphs) was chosen to 
perform further experiments. MOCK = control, MeV = Measles vaccine virus, MeV-
SCD, Gem = gemcitabine. 
 
 
3.1.3.2. 5-FU and MeV-SCD in combination 
 
In general, combination treatment with 5-FU and MeV-SCD was not as efficient 
as combination of gemcitabine and MeV-SCD as tumor cell viabilities were less 
frequently found to undercut 50 % and never undercut 40 %. Moreover, 
differences concerning cell viability between treatment with one agent alone 
and the combination of both were less significant. In MIA PaCa-2, best effects 
were shown for the combination of 12.5 µM 5-FU with an MOI of 0.35 as cell 
viability was between 70 and 80 % for both agents when applied alone and 
about 45 % when combined.  
In PANC-1, cell viability for combination treatment was in all cases between 45 
and 60 % and did not show high meanderings. Best effects were visible for an 
MOI of 0.075 and a 5-FU concentration of 2.5 µM.  
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In BxPC-3, best effects were shown combining 2.5 µM 5-FU with an MOI of 
0.125 of MeV-SCD. Cell viability was between 70 and 80 % for both agents 
when applied alone and about 45 % when combined. All mentioned results 
depicted in Figure 7. 
 
 
 
Cell line  
MeV-SCD 
(MOI) 
5-FU 
(µM) 
MIA PaCa-2 
0.3 7.5 
0.35 10.0 
0.4 12.5 
PANC-1 
0.05 1.25 
0.075 2.5 
0.1 5.0 
BxPC-3 
0.075 2.5 
0.1 5.0 
0.125 7.5 
Table 4. Listing of all MOIs of MeV-SCD and all concentrations of 5-FU 
investigated to approach an adequate dose for combination treatment. Every 
MOI of MeV-SCD was combined with every concentration of 5-FU, resulting in nine 
possibilities for combination in each cell line. For results see Figure 7. 
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A. MIA PaCa-2 
MOI 7.5 µM 5-FU 10 µM 5-FU 12.5 µM 5-FU 
0.3 
   
0.35 
   
0.4 
   
 
B. PANC-1 
MOI 1.25 µM 5-FU 2.5 µM 5-FU 5 µM 5-FU 
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0.075 
 
  
0.1 
  
 
 
C. BxPC-3 
MOI 2.5 µM 5-FU 5 µM 5-FU 7.5 µM 5-FU 
0.075 
  
 
0.1 
   
0.125 
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Figure 7. Preliminary experiments investigating the efficacy of the combination 
of MeV-SCD and 5-Fluorouracil (5-FU) for each cell line (A = MIA PaCa-2, B = 
PANC-1, C = BxPC-3). Three individual MOIs of MeV-SCD and three concentrations of 
5-FU were combined (Table 4) resulting in nine graphs for each cell line. The MOIs / 
concentrations for each cell line were chosen looking for a moderately cytotoxic effect 
when used as a single agent resulting in a remaining cell mass of about 50-80 %. 
MOCK = control, MeV = Measles vaccine virus, MeV-SCD  
 
3.2. Combination of MeV and Gemcitabine 
 
As gemcitabine has been first-line chemotherapeutic agent in pancreatic cancer 
for a long time and still plays an important role, performing experiments 
combining it with OV in more detail seems to be a reasonable approach. 
Moreover, it is the only drug that is approved as single-agent therapy and is 
known to induce senescence (therapy induced senescence = TIS). Including all 
those considerations and the high efficacy that was shown for combination with 
MeV-SCD in the previous experiments, it was self-evident to perform further 
experiments concerning interaction between gemcitabine and MeV-SCD. All 
following experiments were performed with the MOIs of MeV-SCD and the 
gemcitabine concentrations listed in table 5. 
Cell line MOI of MeV-SCD Gemcitabine (µM) 
MIA PaCa-2 0.4 0.03 
PANC-1 0.075 0.075 
BxPC-3 0.125 0.02 
Table 5. MOIs of MeV-SCD and concentrations of gemcitabine chosen for final 
experiments for each cell line.  
 
 
3.2.1. Comparison of SRB assay and MTT assay 
 
After the identification of the accurate doses of gemcitabine and MeV-SCD, 
results of the SRB assay were confirmed using another cell viability assay, the 
MTT assay. The SRB assay measures the remaining cell mass after the 
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fixation of cells whereas the MTT assay measures the activity of cellular 
enzymes, thus the rate of living cells. Results were summarized in one graph to 
compare results of SRB assay and MTT assay directly. Mostly, results only 
varied slightly, which imply that both SRB and MTT assay are adequate for the 
determination of cell viability in these cell lines. All results depicted in Figure 
8B.  
Cell viability undercut 50 % in all cell lines when MeV-SCD and gemcitabine 
were combined which constitutes a considerable cytotoxic effect in contrast to 
the rather low efficacy of the therapeutics when used alone.  
In MIA PACa-2, cell viability was reduced to less than 30 % for combination 
therapy. Using the same concentrations of MeV-SCD (MOI 0.4) and 
gemcitabine (0.03 µM) as single agent, cell viability did not undercut 70 % for 
MeV-SCD and 55 % for gemcitabine (Fig. 8B).  
In PANC-1, cell viability was higher than 65 % (MeV-SCD, MOI 0.075) and 
higher than 75 % (0.075 µM gemcitabine) for single agent treatment and 40-45 
% for the combinatorial approach.  
In BxPC-3, cell viability for MeV-SCD (MOI 0.125) alone was about 80 % and 
65 % for gemcitabine (0.02 µM) alone. Combination of both resulted in a cell 
viability of less than 50 %.  
Of notice, in PANC-1 cells, a significant difference between both assays for the 
treatment with gemcitabine alone was measured (Fig. 8B). Cell viability in the 
MTT assay was about 100 % whereas cell mass in the SRB assay was 
measured as less than 80 %. A likely explanation for that difference is the 
senescence-inducing potency of gemcitabine. Cell metabolism in senescent 
cells remains active, which is a parameter measured by the MTT assay. 
Interestingly, cell viability of the combination of both MeV-SCD and gemcitabine 
was not found to differ between both assays.  
Comparing combination therapy with single-agent therapy, significantly reduced 
cell viability was found in all three cell lines for the combinatorial approach. 
Consequently, it became obvious that both agents did not influence the 
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cytotoxic potency of each other in pancreatic cancer cell lines. To confirm that 
theory, viral replication of MeV-SCD as well as therapy-induced senescence 
(TIS) caused by gemcitabine was tested for combination therapy. 
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Figure 8. Chemovirotherapy employing gemcitabine (GEM) together with MeV-
SCD in three pancreatic cancer cell lines. [88] (A) Setting: tumor cells were infected 
24 hours after plating. Add-on of gemcitabine was performed 3 hours post infection 
(hpi) when medium was changed. Total incubation time of virus was 72 hours. (B) 
(Figure and corresponding description published in [88]) “ Cell viability was 
measured using two different assays [SRB (black bars) and MTT (white bars) assays, 
respectively] and normalized to an uninfected (MOCK-treated) control (set to 100% cell 
viability). MOIs of MeV and Gem concentrations were chosen at low enough levels to 
reduce tumor cell masses <50% when used as a single compound. When used in 
combination, the remaining tumor cell mass was found to be <5% in all three tumor cell 
lines. For MeV, MOIs of 0.4 (MIA PaCa-2), 0.075 (PANC-1) and 0.125 (BxPC-3) were 
chosen, respectively. For Gem, concentrations of 0.03 µM (MIA PaCa-2), 0.075 µM 
(PANC-1) and 0.02 µM (BxPC-3) were used, respectively. Data are presented as the 
mean ± standard deviation of three independent experiments. GEM, gemcitabine; hpi, 
hours post infection; MOIs, multiplicities of infection; MeV, measles vaccine virus; 
SRB, Sulforhodamin B.“ 
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3.3. Virus growth curves 
 
Virus growth curves were generated to measure viral replication within a cell 
line over a period of 96 hours (hours post infection = hpi). Virus was quantified 
in both cell suspension (cell associated virus) and supernatant (released virus) 
of infected cells. MOI and gemcitabine concentration was equal to SRB and 
MTT assays.  
3.3.1. Influence of gemcitabine on viral replication 
 
Viral replication within infected cancer cells constitutes one of the most 
important modes of action of oncolytic virotherapy (OV), as it is indispensable 
for lysis and further infection.  
To elicit the influence of gemcitabine, viral replication was investigated in the 
absence or presence of gemcitabine. Virus growth curves were generated for 
viral replication within cells (Fig. 9, “cell associated virus”, continuous graphs on 
the left) and released virus in supernatant (dotted graphs on the right).  
To compare viral replication of MeV-SCD alone with the combination of MeV-
SCD and gemcitabine, virus growth curves for MeV-SCD alone and for 
combination therapy were generated under the same conditions. MOI of MeV-
SCD and concentrations of gemcitabine were the same as applied for SRB and 
MTT assay.  
In general, viral replication was rather similar for both conditions. For two cell 
lines (MIA PaCa-2 and BxPC-3) viral replication was slightly inhibited by the 
additional treatment with gemcitabine.  
For cell associated virus in MIA PaCa-2, viral titers 72 hpi were about 8 x 106 
plaque forming units (PFU) for MeV-SCD alone and 1 x 106 PFU for the 
combination. 
In BxPC-3, cell associated virus 48 hpi was 1.6 x 103 PFU for MeV-SCD and 
0.17 x 103 PFU for combination.  
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It must be pointed out that cell viability was very likely to be reduced by adding 
gemcitabine (the MOI of MeV-SCD was the same for both conditions). Thus, 
the most probable reason for the diminished viral replication was the reduced 
cell viability and not any mechanism of direct inhibition of viral replication 
caused by gemcitabine. Furthermore, viral replication in BxPC-3 was rather low 
compared to the other two cell lines and did not exceed 104 PFU. To 
investigate that phenomenon more precisely, cell number seeded per well was 
raised to 2 x 104 cells per well and 3 x 104, respectively (for results see 3.3.2.). 
 
  
  
  
Figure 9. (Figure and corresponding description published in [88]) “Virus growth 
curves illustrating the course of viral replication in pancreatic cancer cells 
infected with oncolytic MeV. Virus growth of MeV-SCD (here denoted as MeV) was 
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determined both in cell suspensions (continuous line graphs, cell associated virus) as 
well as in tumor cell culture supernatants (dotted line graphs, released virus). Viral 
replication was compared between: i) Single treated, i.e., ‘only’ infected tumor cells 
(MeV; mono-virotherapy, grey graphs); and ii) chemovirotherapeutic treated tumor 
cells, being infected first and then treated additionally with gemcitabine at 3 hpi 
(MeV+Gem, black graphs). Notably, tumor-cell specific multiplicities of infection of MeV 
and concentrations of Gem were used equal to the concentrations employed before in 
the viability assays (Sulforhodamin B and MTT). Except for the 48-h-value of released 
virus in the cell line BXPC-3, there was no statistically significant difference between 
the values of viral growth with or without Gem. All statistical analyses were conducted 
with Bonferroni's multiple comparison test. *P<0.05 vs. MeV-Gem. PFU, plaque 
forming units; n.s., not significant; hpi, hours post infection; GEM, gemcitabine; MeV, 
measles vaccine virus.“ 
 
3.3.2. Increase of seeded cell number (BxPC-3) 
 
As mentioned in section 3.4.1. and shown in Figure 9, viral replication of MeV-
SCD in the tumor cell line BxPC-3 was rather low compared to the other two 
cell lines. To investigate that phenomenon in more detail, the cell number 
seeded per well was raised. Cell mass was duplicated (2 x 105) and triplicated 
(3 x 105). Experiments were performed exactly as previous ones. To facilitate 
comparing the differences of the different cell numbers, replication curves of 
one entity (e.g. cell associated virus of MeV-SCD without gemcitabine) were 
visualized in one graph.  
As a result, viral titers were again in all cases found to be lower than 1 x 104 
PFU and compared to the original cell number no significant differences in viral 
replication were found. 
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Figure 10. Comparison of viral replication quantities using different cell numbers 
in the cell line BxPC-3. Viral replication was not increased by the duplicated and 
triplicated cell number in comparison to the original experiments. Viral peak titers 
always remained below 104 PFU/ml independently of cell number or presence of 
gemcitabine. 
 
 
 
3.4. Induction of senescence 
 
As mentioned before, gemcitabine is able to induce senescence (therapy 
induced senescence = TIS) in viable cells, which is defined as a permanent cell 
cycle arrest. The interesting question concerning combination therapy was, if 
senescence can be induced by gemcitabine in MeV-SCD infected cells. 
Obviously, results had to be surveyed considering whether viral replication was 
possible in remaining tumor cells, although they were senescent. Another 
interesting aspect was to investigate in more detail the mutual influence of both 
therapeutics when administered simultaneously.  
3.4.1. Influence of MeV-SCD infection on therapy-induced 
senescence 
 
Light microscopically, all cell lines revealed signs of senescence, which are for 
example an enlarged and flattened phenotype. To detect senescent cells, the 
senescence-associated -galactosidase (SA--Gal) assay was used. The 
chosen cell line for the SA--Gal assay was MIA PaCa-2 as this method hardly 
works in the other two cell lines. Senescent cells were stained blue (-
galactosidase positive cells) and counted normalized to the total number of 
cells. As positive control, 100 µM gemcitabine was used. To make sure that the 
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concentration of gemcitabine (0.03 µM) that was used for previous experiments 
was able to induce senescence, the assay was performed with cells treated 
with 0.03 µM gemcitabine alone and with a combination of gemcitabine and an 
MOI of 0.4 of MeV-SCD.  
As a result, both gemcitabine alone and the combination revealed the same 
potency to induce senescence as the positive control, which was about 70 to 80 
% (Fig. 11A). As negative control, MOCK-treated cells were investigated for 
senescence. Furthermore, cells were treated with an MOI of 0.4 of MeV-SCD 
alone. Cells were tested negatively for senescence, as -galactosidase positive 
cells were less than 15 % (Fig.11A). 
 
  
Figure 11. (Figure and corresponding description published in [88]) “SA-β-Gal 
assay illustrating therapy-induced senescence in MIA PaCa-2 cells. (A) Tumor 
cells were either infected with the oncolytic MeV-SCD (here denoted as MeV) or 
treated with Gem at 3 hpi, and underwent combined chemovirotherapeutic treatment 
(MeV+Gem) or were left untreated (MOCK); pos. control: Gem 100 µM; then, 
expression of SA-β-gal was determined 72 h later. Statistical analyses were conducted 
with an unpaired t-test, confidence interval 95% and two-tailed. (B) Time dependency 
of senescence induction. Gem (0.03 µM) was added either at 3, 24 or 48 hpi. 
Expression of SA-β-gal was determined again at 72 hpi. There was no statistically 
significant impairment of induction of senescence by the presence of virus. Statistical 
analyses were conducted with Bonferroni's multiple comparison test. hpi, hours post 
infection; SA-β-Gal, senescence-associated β-galactosidase; Gem, gemcitabine; hpi, 
hours post infection; pos. control, positive control; n.s., not significant; MeV, measles 
vaccine virus.“ 
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3.4.2. Time-dependency of senescence induction 
 
For the experiments described in 3.4.1., gemcitabine was added 3 hours post 
infection (hpi), which constitutes the same pattern as in the previous 
experiments. Another interesting issue was whether the time point of the add-
on of gemcitabine after the virus infection with MeV-SCD had any influence on 
the potency of gemcitabine to induce senescence. The later the add-on of 
gemcitabine was performed, the more virus particles were allowed to replicate 
before induction of senescence took place.  
To investigate if the time point of the addition of gemcitabine had any influence 
on its efficacy concerning senescence induction, gemcitabine was either added 
24 hpi or 48 hpi. Incubation time was 72 hours after the add-on of gemcitabine 
to ensure the same incubation time for gemcitabine as in previous experiments.  
As shown in Figure 9, viral replication either reaches a peak (cell line BxPC-3) 
or a plateau (cell lines MIA PaCa-2 and PANC-1) 48 hpi. Thus, it was not 
necessary to investigate later time points after viral infection. Again, 
gemcitabine was also added without infection of MeV-SCD at the same time 
points (24 h, 48 h) to ensure senescence-inducing potency was present. MOI of 
MeV-SCD and gemcitabine concentrations were the same as in previous 
experiments. The same applied for positive and negative control.  
Taken together, the time point of the add-on of gemcitabine did not alter the 
efficacy of senescence induction. For both time points, more than 75 % of cells 
were found to be senescent, as depicted in Figure 11B. 
 
3.4.3. Visualization of a contemporaneous presence of 
senescence and MeV-infection in the same cells 
 
To reassure that senescence and viral infection did not only occur as side-by-
side phenomena but also simultaneously in the same tumor cells, β-
galactosidase positive MIA PaCa-2 cells were analyzed microscopically. For 
this purpose MeV-GFP was used, a measles vaccine virus encoding a green 
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fluorescent marker protein, which can be detected by fluorescence microscopy. 
Senescence is easy to visualize not only by an enlarged and flattened 
phenotype of the cell, but also by the light blue color in the SA-β-Gal assay. 
Therefore, cells were infected and treated as in previous experiments with the 
only difference that MeV-GFP was used instead of MeV-SCD.  
At 72 hours post infection, green fluorescent cells were detected by 
fluorescence microscopy (Figure 12B and 12E). The SA-β-Gal assay was 
performed subsequently as fluorescence cannot be detected in cells, which had 
been fixed and stained before.  
As a result, SA-β-Gal positive cells showing blue staining were identified by 
bright field microscopy of the same area (Figure 12A and 12D). Additionally, 
light microscopy revealed the enlarged and flattened phenotype being typical of 
senescence (Fig. 12C and 12F). As a further result, Figure 12 shows that MeV 
infected cells showing green fluorescence are able to undergo senescence 
(Fig. 12A-C). Higher magnification revealed that also a syncytium being 
characteristic for MeV infection displayed a senescent phenotype (Fig. 12D-F). 
Figure 12. (Figure and corresponding description published in [88]) “Senescence 
patterns induced by gemcitabine in pancreatic cancer cells infected with 
oncolytic MeV. Upper panel (all magnification, ×4): (A) MIA PaCa-2 tumor cells 
infected with the GFP marker gene encoding oncolytic MeV (MeV-GFP) exhibited blue 
staining of senescence-associated β-galactosidase, detected by bright field 
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microscopy. (B) Visualization of MeV-GFP infected tumor cells by fluorescence 
microscopy. (C) Light microscopy of the same sector exhibiting an enlarged and 
flattened phenotype of tumor cells, being characteristic for the induction of therapy-
induced senescence. Red dotted circles indicate examples of MeV-GFP infected 
senescent tumor cells. Lower panel (all magnification, ×10): (D) Higher magnification 
of a MeV (MeV-GFP) induced syncytium of MIA-PaCa-2 tumor cells exhibiting a blue 
colored (β-galactosidase positive) senescent phenotype. (E) Proving infection with 
MeV-GFP, this syncytium (encircled in red) exhibited a strong GFP-mediated 
fluorescence signal. (F) Light microscopy depicted the multinucleated phenotype being 
typical for MeV-induced syncytia. Tumor cells (MIA PaCa-2) were treated with the 
respective concentrations used in the combination experiments (MOI of MeV: 0.4; 
concentration Gem: 0.03 µM), pictures were taken at 72 hpi. Gem, gemcitabine; hpi, 
hours post infection; MeV, measles vaccine virus; GFP, green fluorescent protein.“ 
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4. Discussion 
 
Oncolytic virotherapy provides a new perspective concerning the therapy of 
cancer. Within the numerous oncolytic viruses which are currently investigated 
for their efficacy in cancer cells, oncolytic Measles vaccine viruses (MeV) 
constitute a novel approach to overcome therapeutic resistance of pancreatic 
cancer, yet resistances against virotherapy exist or arise [78]. Therefore, novel 
combination strategies to treat pancreatic cancer have to be developed.  
As gemcitabine constitutes the first-line therapeutic for the treatment of locally 
advanced or metastatic pancreatic cancer, we investigated whether the 
combination of MeV with that very agent showed superior effects when 
compared to either agent alone. The same was performed using 5-Fluorouracil 
(5-FU) in combination with MeV. As our virotherapy regimen including 
gemcitabine showed more promising results than the combination with 5-FU, 
viral replication and the influence of virus on senescence, caused by 
gemcitabine, were also investigated. 
Cell viability assays showed a superior cytotoxic effect for the combination of 
MeV and gemcitabine when compared to both therapeutics administered as 
single agents. These results are also interesting for a possible transfer to in 
vivo treatment considering that lower drug concentrations lead to lower side-
effects, as already shown in combination of gemcitabine with myxoma virus 
[89]. Two different assays were performed: SRB assay measuring cell mass 
and MTT assay measuring metabolic activity of cells. For the pancreatic cancer 
cell lines MiaPaCa-2 and BxPC-3 results were quite similar. In contrast, for 
PANC-1 tumor cells, when treated solely with gemcitabine, we observed a 
significant difference between the results of the SRB and the MTT assay (see 
Fig. 8B; third pair of bars from the left): cell viability in the MTT assay was about 
100% whereas cell mass in the SRB assay was measured as less than 80%. A 
likely explanation for that difference is the senescence-inducing potency of 
gemcitabine. Cell metabolism in senescent cells remains active [90]. The MTT 
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assay measures cell viability via the activity of cell metabolism, which can lead 
to varieties concerning assay results [91]. Interestingly, cell viability of the 
combination of both MeV and gemcitabine was not found to differ between both 
assays, both cell mass and cell metabolism were diminished to a similar 
amount. Thus, no disadvantages due to the “side effect” senescence were 
detectable concerning efficiency of the combination therapy, which was also 
verified by virus growth curves.  
The combination of 5-FU and MeV showed better cytotoxic effects on the 
investigated cancer cell lines than each agent alone. Thus, it can be assumed, 
that there is no reciprocal impairment of the efficacy of both agents, when 
combined. However, results imply (see Fig. 7 in comparison to Fig. 6), that the 
efficacy of the combination therapy succumbs the combination of MeV and 
gemcitabine. Moreover, 5-FU alone usually is not used as chemotherapy in 
pancreatic cancer in a palliative setting. For those reasons, in this work, the 
combination of gemcitabine and MeV has been studied in more detail. The 
influence of MeV on senescence or the influence of gemcitabine and 
senescence on viral growth was investigated. As a perspective for future 
experiments, another pragmatic chemovirotherapeutic approach containing 5-
FU could be the combination of MeV with FOLFIRINOX, which consists of 
leucovorin, 5-FU, irinotecan and oxaliplatin. FOLFIRINOX is another 
therapeutic regimen used in advanced pancreatic cancer. As there are three 
chemotherapeutic drugs included, side effects are more severe ([17], see 
introduction). Consequently, it is applicable only for the fitter patients. If the 
results for chemovirotherapy with FOLFIRINOX would be similar to the ones 
with gemcitabine or 5-FU, combination therapy could also be a future 
perspective to lower the chemotherapy dosage and hence the mentioned side 
effects. 
The phenomenon of senescence is a highly discussed mechanism and 
intensely researched, as its role in the development and suppression of cancer 
is still not certain [30, 92]. Several drugs - including gemcitabine - are able to 
induce senescence in cancer cells resulting in a permanent cell cycle arrest 
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and consequently maintaining cells in a less malignant state [27]. As 5-FU is 
also capable to induce senescence [93], the question might arise, why 
senescence has not been investigated in our work. As 5-FU mainly induces 
senescence via reactive oxygen species (ROS), mostly endothelial cells are 
being converted in a senescent state when treated with 5-FU [93]. The cells 
being used in this work reveal rather epithelial and mesenchymal 
characteristics [94], which is a likely explanation for the absence of senescence 
in these cases. 
As the induction of senescence is not necessarily irreversible, therapeutic 
approaches have to be developed, which efficiently eliminate senescent cells. 
In a previous study, Weiland et al. from our group could show that MeV can 
infect, replicate within and lyse senescent cells including pancreatic cancer 
cells even more efficiently than non-senescent cells [27]. In vivo, it is almost 
impossible to ensure the sequence of application to every single cell, if a 
combination therapy is aspired. Therefore, we wanted to complement the 
previously mentioned finding and investigated if senescence can be induced in 
MeV-infected cells. For this purpose, we first infected pancreatic cancer cells 
with MeV and then added gemcitabine at several different time points up to 48 
hours post infection with MeV. The results point out that senescence-induction 
is not altered by viral infections independently of the time point of the add-on of 
gemcitabine.  
In summary these findings point out that senescence and MeV infection are not 
inconsistent cellular mechanisms when cytotoxicity is aimed at. No matter 
which mode of application was chosen concerning sequence of administration, 
induction of senescence led to an increased oncolytic cell death when 
compared to MeV infection alone. Similar results were obtained for the 
combination of the oncolytic coxsackievirus A21 in combination with the 
senescence inducing agent doxorubicine hydrochloride in a work published by 
Skelding et al. in 2012. Simultaneous application of virus and drug as well as 
infection and addition of the chemotherapeutic 24 h later showed synergistic 
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effects concerning cytotoxicity. No influence of doxorubicine on viral replication 
was observed [95].  
Gemcitabine has already been co-administered with different oncolytic viruses. 
Wennier et al. treated pancreatic carcinoma cell lines with gemcitabine in 
combination with myxoma virus (MYXV). The drug was found to inhibit viral 
gene expression upon simultaneous administration. Sequential treatment, 
however, resulted in a striking decrease in cell viability when compared to the 
respective mono-therapies. Interestingly, the optimal sequence (drug first or 
virus first) was dependent on the cell line [89]. Gemcitabine was also shown to 
increase the oncolytic efficiency of the rat parvovirus H-1PV in pancreatic 
carcinoma cells when administered 24 h before the virus [96].  
In our study we could show that (1) MeV and the chemotherapeutic compounds 
gemcitabine and 5-FU did not impair the efficacy of each other when 
administered together. (2) As many other virochemotherapy regimens, which 
have been tested so far, the combination of MeV and gemcitabine showed no 
reduced efficacy, no matter what mode and sequence of administration was 
chosen. Nevertheless, it is always important to consider the tumor entity, as 
differences of therapeutic efficacy exist depending on the sequence of 
application. 
To take a closer look at the impact of gemcitabine on MeV, the viral replication 
behavior of MeV in the presence of gemcitabine has been investigated as well. 
Viral replication is a central mechanism for the efficacy of OV as it ensures a 
multiplication of the oncolytic potency as well as further spreading of viral 
particles [97]. Thus, the influence of gemcitabine on viral replication was an 
important aspect to investigate. As illustrated in Fig. 9, we observed a slight 
decrease in viral replication when gemcitabine was administered as an add-on. 
The lowest viral titers and the most distinct difference concerning viral growth 
with or without gemcitabine were detected in the cell line BxPC-3. Therefore, 
the experiment was repeated using two- and three-fold numbers of seeded 
cells to investigate whether it had an influence on the results. The intention was 
also to see whether a putative cytotoxicity of gemcitabine had a major impact 
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on BxPC-3 tumor cells and, as a result, viral growth was diminished due to 
decreased tumor cell number. As visible in the results, increase of seeded cell 
number had no overwhelming influence on viral growth. It is most likely, that 
viral growth is more active in the other two cell lines than in BxPC-3. That result 
is also mirrored by the decreased cytotoxicity in the combination therapy of 
gemcitabine and MeV in BxPC-3 in comparison to the other two cell lines. 
Eisenberg et al. were able to show that replication of oncolytic herpes virus 
NV1066 increases in the presence of gemcitabine [98]. In this study, a different 
application scheme was used with gemcitabine being added 6 h prior to 
infection. The reduced viral replication depicted in our work might be caused by 
the reduced cell number due to the cytotoxic effect of gemcitabine. As the 
presence of vital cells is crucial for the replication of MeV, fewer cells result in 
lower viral titers.  
Direct alteration of viral replication by gemcitabine is also very likely as 
gemcitabine was originally developed as antiviral therapy and shows antiviral 
activity against RNA and DNA viruses [99, 100]. However, viral replication was 
only decreased but not suppressed and cytotoxicity was significantly higher 
with MeV than with gemcitabine alone. In numerous other works, a potentiation 
of viral replication was described when combined with chemotherapy or 
radiation [98, 101, 102]. The current explanation for that phenomenon is, in a 
simplified view, the host cellular stress response caused by chemotherapy or 
radiation, which facilitates viral entry, replication and lysis, as the host cell is 
weakened.  
Summarizing all those findings, we can deduce that a certain impairment of 
viral replication either caused by the reduced cell number or direct antiviral 
activity or both can be detected. As gemcitabine was administered only at 
distinct concentrations, it cannot be entirely excluded, that viral replication 
might be impaired to a larger extent in vivo. To answer that question, similar 
experiments should be performed using cell lines being more resistant towards 
gemcitabine, as the cytotoxicity of gemcitabine in higher concentrations would 
be lethal for the cell lines used in this work. Enhanced viral replication caused 
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by the additional cellular stress due to gemcitabine with simultaneously reduced 
cell number was neither proved nor disproved. Regardless of those 
considerations, viral replication was rather active and not suppressed at all by 
gemcitabine and showed a significant impact concerning cytotoxicity. 
Combination of gemcitabine and MeV constitutes a reasonable new approach 
to overcome therapeutic resistance of pancreatic cancer cells in vitro. We were 
able to show that a combination of rather low concentrations of both 
therapeutics which were clearly suboptimal in terms of cytotoxicity led to a 
significant increase in cytotoxicity in three cell lines when compared to single 
agent treatment. It remains to be determined, whether there is a distinct 
molecular pathway that leads to the observed combinatorial effect. However, 
both therapeutics were shown to work well together and did not alter 
significantly efficacy of each other. For further research, it is indispensable to 
transfer our findings to in vivo to find out about possible obstacles and the most 
advantageous way of therapeutic application. For example, the investigation of 
viral replication behavior in combination with gemcitabine within a solid tumor 
would constitute an important approach to find out more about possible mutual 
interactions. Moreover, besides virotherapy, there are other novel therapeutics 
with the potency to revolutionize cancer therapy. An example to mention is the 
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) erlotinib, 
which constitutes an alternative treatment strategy in combination with 
gemcitabine in advanced pancreatic cancer [16, 103], but also epigenetic drugs 
being currently under investigation for a combination treatment with 
virotherapeutics in cancer [104, 105] or the ataxia telangiectasia mutated 
protein (ATM), which potentiated the replication of reovirus in canine melanoma 
cell lines [106]. Another strategy investigated in glioblastoma cells is the 
application of chemotherapy in combination with Measles Vaccine Virus and 
radiotherapy resulting in synergistic therapeutic effects and a pro-inflammatory 
phenotype in vitro [107]. It is still to consider, whether the add-on of further 
cancer therapeutics will lead to further benefit in the outcome. 
Discussion 
_______________________________________________________________ 
65 
Concerning application of the therapeutics, it is very important to optimize 
delivery of therapeutics especially in pancreatic cancer, as it is hard to reach 
systemically due to its scarce vascularization and thus hypoxia as described 
before.  
In general, as virotherapy has not entered a status of widespread clinical 
routine, many questions remain to be answered concerning application, dosage 
and frequency, which are currently under investigation [108]. Therefore, 
alternative modes of application should be tested in vivo, e.g. intratumoral, 
intraperitoneal (i.p.) [109] or even locoregional, e.g. by hepatic arterial infusion 
[110]. 
New findings concerning tumor biology should be taken into consideration 
searching for other therapeutic options. It is very important to analyze different 
therapeutic regimens [82], and the influence of the immune system on 
virotherapy - considering both “negative” aspects as it weakens viral infection 
and “positive” aspects as the activation of the immune system leads to 
antitumor immune response [111, 112]. Addressing this predominantly 
unsolved issue, three strategies have been described regarding oncolytic 
measles virotherapy: (1) the suppression of antiviral immunity in patients or (2) 
shielding of viral particles from detection of the immune system or (3) 
enhancing immune evasion of virus [113]. One approach to suppress antiviral 
immunity is the coadministration of cyclophosphamide to avoid antibody-
mediated immune-response [114]. Concerning shielding of viral particles, 
carrier cells infected with virus, such as T-cells, monocytes or mesenchymal 
stem cells are under investigation [115] [113, 116]. 
Other approaches exploit the interaction of the virus with the immune system, 
such as the genetically modified herpes simplex virus type 1, known as 
talimogene laherparepvec (T-VEC), which was approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of malignant melanoma in 2015 
[47]. In the randomized open label phase-III OPTiM-trial, patients with un-
resectable IIIB-IVM1c-stage malignant melanoma received T-VEC intratumoral. 
T-VEC is attenuated, as herpes neurovirulence viral genes are replaced by the 
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coding sequence for granulocyte-macrophage colony-stimulating factor (GM-
CSF) to enhance T-cell responses. A control group received GM-CSF alone. 
The application of T-VEC resulted in better durable response rates (DRR) and 
overall survival (OS) without fatal adverse events reported [48, 117, 118].  
As checkpoint inhibitors constitute a revolutionary finding in the field of cancer 
immunotherapy leading to profound antitumor immune response [119, 120], 
combination with oncolytic virotherapy appears as a rather worthwhile 
investigation. In their work, Engeland et al. [121] were able to show, that 
combination of CTLA-4 and PD-L1 inhibitors and measles virus resulted in 
delayed tumor progression and prolonged median overall survival. Interestingly, 
in this work, measles virus was used as vector for antibodies against CTLA-4 
and PD-L1. An immunocompetent murine model with subcutaneous melanoma 
was treated intratumoral, leading to an increase of CD3+ and partly also CD8+ 
T-cells. A similar approach was performed by Dias et al. [122], using adeno-
virus as a vector to encode an anti-CTLA-4 monoclonal antibody (mAb), 
resulting in higher intratumoral concentrations of the mAb than in plasma. Both 
works constitute interesting approaches for combination regimens, leading to a 
more targeted and more efficient checkpoint inhibition and thus to less side 
effects. Another interesting approach in the field of combination of OV and 
checkpoint inhibitors is a work by Mullins-Dansereau et al., exploring OV as a 
neoadjuvant therapeutic regimen in a murine model of breast cancer with post-
operative re-challenge of tumor and treatment with immune checkpoint inhibitor 
at relapse [123]. Mice treated with OVs showed a higher rate of cure and 
smaller secondary tumors and less metastases. The effect was only observed 
in a immunocompetent model, suggesting, that the result was immune-
mediated [123]. 
In a recently published review the necessity of a very profound investigation 
and understanding of tumor biology was pointed out as well [124]. Moreover, it 
was accented, that identification of synergistically working chemovirotherapy is 
urgently needed - aiming not only for an exploitation of cytotoxicity but also for 
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an alteration of the immunosuppressive microenvironment of pancreatic cancer 
[121, 125].  
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5. Summary 
 
Current therapeutic options for locally advanced or metastatic pancreatic 
cancer still are not able to improve the prognosis of patients long-lasting. Thus, 
it is more than urgent to find new strategies to overcome therapeutic resistance 
and inefficiency, respectively, by establishing novel combinatorial approaches 
encompassing new therapeutic principles. 
“Oncolytic virotherapy with vaccine viruses employs replicative vectors, which 
quite selectively infect tumor cells leading to massive virus replication followed 
by subsequent profound tumor cell death (oncolysis). Measles vaccine virus 
(MeV) has already shown great oncolytic activity against different types of 
cancers, including pancreatic cancer. Gemcitabine is a first line chemo-
therapeutic drug used for pancreatic cancer in palliative treatment plans. 
Furthermore, this drug can be used to induce senescence, a permanent cell 
cycle arrest, in tumor cells. In our preclinical work, three well-characterized 
immortalized human pancreatic cancer cell lines were used to investigate the 
combinatorial effect of MeV-based virotherapy together with the chemo-
therapeutic compound gemcitabine. Viability assays revealed that the 
combination of only small amounts of MeV together with subtherapeutic 
concentrations of gemcitabine resulted in a tumor cell mass reduction of > 50%. 
To further investigate the replication of the oncolytic MeV vectors under these 
distinct combinatorial conditions, viral growth curves were generated. As a 
result, viral replication was found to be only slightly diminished in the presence 
of gemcitabine. As gemcitabine induces senescence, the effect of MeV on that 
phenomenon was explored using a senescence-associated β-galactosidase 
assay. Notably, gemcitabine-induced tumor cell senescence was not impaired 
by MeV. Accordingly, the chemovirotherapeutic combination of gemcitabine 
plus oncolytic MeV constitutes a novel therapeutic option for advanced 
pancreatic carcinoma that is characterized by the mutual improvement of the 
effectiveness of each therapeutic component.“ [88] 
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5.1 Zusammenfassung 
 
Zur Zeit sind die für das lokal fortgeschrittene oder metastasierte Pankreas-
karzinom verfügbaren therapeutischen Optionen noch nicht in der Lage, die 
Langzeit-Prognose der Patienten zu verbessern. Die onkolytische Virotherapie 
mit Impfviren stellt eine neuartige Therapieoption dar, wobei replizierende 
Vektoren mit einer überwiegenden Selektivität für maligne Zellen Tumorgewebe 
infizieren, was zu einer massiven Tumorzell-gestützten Virusreplikation und 
darauf folgendem Tumor-Zelltod führt. Für Masern-Impfviren (MeV) konnte 
schon eine sehr gute onkolytische Aktivität bei verschiedenen Krebsarten 
nachgewiesen werden. Gemcitabine stellt eine etablierte Chemotherapie bei 
Pankreaskarzinom dar. Darüber hinaus kann dieses Medikament verwendet 
werden, um Seneszenz, einen permanenten Zellzyklusarrest, zu induzieren. 
Für unsere präklinische Arbeit wurden drei humane Pankreaskarzinom-
Zelllinien verwendet, um den Kombinations-Effekt von MeV als 
Virotherapeutikum mit Gemcitabine zu untersuchen. In Zellviabilitäts-Assays 
konnte gezeigt werden, dass die Kombination aus einer geringen Anzahl an 
infektiösen MeV-Viruspartikeln (unterschwellig lytisch) zusammen mit sub-
therapeutischen Konzentration des Chemotherapeutikums Gemcitabine zu 
einer Reduktion der Tumor-Zellzahlen von über 50 % führte. Um die 
Replikation von MeV unter diesen speziellen ‘Kombinations-Bedingungen’ 
weiter zu untersuchen, wurden Virus-Wachstumskurven erstellt. Es zeigte sich, 
dass die Virusreplikation leicht vermindert war, verglichen mit der Replikation in 
Abwesenheit von Gemcitabine. Da Gemcitabine Seneszenz induzieren kann, 
wurde der Einfluss von MeV auf dieses Phänomen mit Seneszenz-assoziierter 
β-Galactosidase (SA-β-gal) untersucht. Interessanterweise wurde die von 
Gemcitabine verursachte Tumorzell-Seneszenz nicht unterbunden durch die 
Anwesenheit von MeV. Zusammenfassend stellt die Chemovirotherapie 
bestehend aus einer Kombination von Gemcitabine mit Masern-Impfviren eine 
neuartige Therapieoption dar, die sich darin auszeichnet, dass sich beide 
Therapeutika in Kombination gegenseitig verstärken können.
  
 
70 
6. Appendix 
 
 
6.1. References 
 
 
1. Yeo, T.P., Demographics, Epidemiology, and Inheritance of Pancreatic 
Ductal Adenocarcinoma. Semin Oncol, 2015. 42(1): p. 8-18. 
2. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA 
Cancer J Clin, 2015. 65(1): p. 5-29. 
3. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer Statistics, 2017. CA 
Cancer J Clin, 2017. 67(1): p. 7-30. 
4. Bilimoria, K.Y., et al., Validation of the 6th edition AJCC Pancreatic 
Cancer Staging System: report from the National Cancer Database. 
Cancer, 2007. 110(4): p. 738-44. 
5. Ady, J.W., Heffner, J, Oncolytic viral therapy for pancreatic cancer: 
current research and future directions. Oncolytic Virotherapy, 2014. 
3(2014): p. 11. 
6. Iacobuzio-Donahue, C.A., et al., Genetic basis of pancreas cancer 
development and progression: insights from whole-exome and whole-
genome sequencing. Clin Cancer Res, 2012. 18(16): p. 4257-65. 
7. Grippo, P.J., et al., Preinvasive pancreatic neoplasia of ductal phenotype 
induced by acinar cell targeting of mutant Kras in transgenic mice. 
Cancer Res, 2003. 63(9): p. 2016-9. 
8. Feig, C., et al., The pancreas cancer microenvironment. Clin Cancer 
Res, 2012. 18(16): p. 4266-76. 
9. Provenzano, P.P., et al., Enzymatic targeting of the stroma ablates 
physical barriers to treatment of pancreatic ductal adenocarcinoma. 
Cancer Cell, 2012. 21(3): p. 418-29. 
10. Momi, N., et al., Discovering the route from inflammation to pancreatic 
cancer. Minerva Gastroenterol Dietol, 2012. 58(4): p. 283-97. 
11. Clark, C.E., et al., Dynamics of the immune reaction to pancreatic cancer 
from inception to invasion. Cancer Res, 2007. 67(19): p. 9518-27. 
12. Thiery, J.P., et al., Epithelial-mesenchymal transitions in development 
and disease. Cell, 2009. 139(5): p. 871-90. 
13. Beuran, M., et al., The epithelial to mesenchymal transition in pancreatic 
cancer: A systematic review. Pancreatology, 2015. 15(3): p. 217-25. 
14. Clancy, T.E., Surgery for Pancreatic Cancer. Hematol Oncol Clin North 
Am, 2015. 29(4): p. 701-16. 
15. Burris, H.A., 3rd, et al., Improvements in survival and clinical benefit with 
gemcitabine as first-line therapy for patients with advanced pancreas 
cancer: a randomized trial. J Clin Oncol, 1997. 15(6): p. 2403-13. 
16. Moore, M.J., et al., Erlotinib plus gemcitabine compared with 
gemcitabine alone in patients with advanced pancreatic cancer: a phase 
  
 
71 
III trial of the National Cancer Institute of Canada Clinical Trials Group. J 
Clin Oncol, 2007. 25(15): p. 1960-6. 
17. Conroy, T., et al., FOLFIRINOX versus gemcitabine for metastatic 
pancreatic cancer. N Engl J Med, 2011. 364(19): p. 1817-25. 
18. Von Hoff, D.D., et al., Gemcitabine plus nab-paclitaxel is an active 
regimen in patients with advanced pancreatic cancer: a phase I/II trial. J 
Clin Oncol, 2011. 29(34): p. 4548-54. 
19. Frese, K.K., et al., nab-Paclitaxel potentiates gemcitabine activity by 
reducing cytidine deaminase levels in a mouse model of pancreatic 
cancer. Cancer Discov, 2012. 2(3): p. 260-9. 
20. Hoy, S.M., Albumin-bound paclitaxel: a review of its use for the first-line 
combination treatment of metastatic pancreatic cancer. Drugs, 2014. 
74(15): p. 1757-68. 
21. Gresham, G.K., et al., Chemotherapy regimens for advanced pancreatic 
cancer: a systematic review and network meta-analysis. BMC Cancer, 
2014. 14: p. 471. 
22. Huang, P., et al., Action of 2',2'-difluorodeoxycytidine on DNA synthesis. 
Cancer Res, 1991. 51(22): p. 6110-7. 
23. Corbo, V., G. Tortora, and A. Scarpa, Molecular pathology of pancreatic 
cancer: from bench-to-bedside translation. Curr Drug Targets, 2012. 
13(6): p. 744-52. 
24. Shore, S., et al., Review article: chemotherapy for pancreatic cancer. 
Aliment Pharmacol Ther, 2003. 18(11-12): p. 1049-69. 
25. Heinemann, V., Gemcitabine: progress in the treatment of pancreatic 
cancer. Oncology, 2001. 60(1): p. 8-18. 
26. Hayflick, L., The Limited in Vitro Lifetime of Human Diploid Cell Strains. 
Exp Cell Res, 1965. 37: p. 614-36. 
27. Weiland, T., et al., Enhanced killing of therapy-induced senescent tumor 
cells by oncolytic measles vaccine viruses. Int J Cancer, 2014. 134(1): p. 
235-43. 
28. Dimri, G.P., et al., A biomarker that identifies senescent human cells in 
culture and in aging skin in vivo. Proc Natl Acad Sci U S A, 1995. 92(20): 
p. 9363-7. 
29. Lee, B.Y., et al., Senescence-associated beta-galactosidase is 
lysosomal beta-galactosidase. Aging Cell, 2006. 5(2): p. 187-95. 
30. Rodier, F. and J. Campisi, Four faces of cellular senescence. J Cell Biol, 
2011. 192(4): p. 547-56. 
31. Acosta, J.C., et al., Chemokine signaling via the CXCR2 receptor 
reinforces senescence. Cell, 2008. 133(6): p. 1006-18. 
32. Coppe, J.P., et al., Senescence-associated secretory phenotypes reveal 
cell-nonautonomous functions of oncogenic RAS and the p53 tumor 
suppressor. PLoS Biol, 2008. 6(12): p. 2853-68. 
33. Dock, G., The influence of complicating diseases upon leukemia. Am J 
Med Sci, 1904. 127: p. 30. 
34. Pelner, L., G.A. Fowler, and H.C. Nauts, Effects of concurrent infections 
and their toxins on the course of leukemia. Acta Med Scand Suppl, 
1958. 338: p. 1-47. 
  
 
72 
35. Bierman, H.R., et al., Remissions in leukemia of childhood following 
acute infectious disease: staphylococcus and streptococcus, varicella, 
and feline panleukopenia. Cancer, 1953. 6(3): p. 591-605. 
36. Sinkovics, J. and J. Horvath, New developments in the virus therapy of 
cancer: a historical review. Intervirology, 1993. 36(4): p. 193-214. 
37. Bluming, A.Z. and J.L. Ziegler, Regression of Burkitt's lymphoma in 
association with measles infection. Lancet, 1971. 2(7715): p. 105-6. 
38. Zygiert, Z., Hodgkin's disease: remissions after measles. Lancet, 1971. 
1(7699): p. 593. 
39. Kelly, E. and S.J. Russell, History of oncolytic viruses: genesis to genetic 
engineering. Mol Ther, 2007. 15(4): p. 651-9. 
40. Hoster, H.A., R.P. Zanes, Jr., and E. Von Haam, Studies in Hodgkin's 
syndrome; the association of viral hepatitis and Hodgkin's disease; a 
preliminary report. Cancer Res, 1949. 9(8): p. 473-80. 
41. Asada, T., Treatment of human cancer with mumps virus. Cancer, 1974. 
34(6): p. 1907-28. 
42. Moore, A.E., Effects of viruses on tumors. Annu Rev Microbiol, 1954. 8: 
p. 393-410. 
43. Southam, C.M. and A.E. Moore, Clinical studies of viruses as 
antineoplastic agents with particular reference to Egypt 101 virus. 
Cancer, 1952. 5(5): p. 1025-34. 
44. Cassel, W.A. and R.E. Garrett, Newcastle Disease Virus as an 
Antineoplastic Agent. Cancer, 1965. 18: p. 863-8. 
45. Cassel, W.A. and D.R. Murray, A ten-year follow-up on stage II 
malignant melanoma patients treated postsurgically with Newcastle 
disease virus oncolysate. Med Oncol Tumor Pharmacother, 1992. 9(4): 
p. 169-71. 
46. Garber, K., China approves world's first oncolytic virus therapy for 
cancer treatment. J Natl Cancer Inst, 2006. 98(5): p. 298-300. 
47. AMGEN. FDA Approves IMLYGIC (Talimogene Laherparepvec) As First 
Oncolytic Viral Therapy In The US. 2015. 
48. Andtbacka, R.H., et al., Talimogene Laherparepvec Improves Durable 
Response Rate in Patients With Advanced Melanoma. J Clin Oncol, 
2015. 33(25): p. 2780-8. 
49. Dorig, R.E., et al., The human CD46 molecule is a receptor for measles 
virus (Edmonston strain). Cell, 1993. 75(2): p. 295-305. 
50. Russell, S.J. and K.W. Peng, Viruses as anticancer drugs. Trends 
Pharmacol Sci, 2007. 28(7): p. 326-33. 
51. Anderson, B.D., et al., High CD46 receptor density determines 
preferential killing of tumor cells by oncolytic measles virus. Cancer Res, 
2004. 64(14): p. 4919-26. 
52. Msaouel, P., A. Dispenzieri, and E. Galanis, Clinical testing of 
engineered oncolytic measles virus strains in the treatment of cancer: an 
overview. Curr Opin Mol Ther, 2009. 11(1): p. 43-53. 
53. Forbes, N.E., R. Krishnan, and J.S. Diallo, Pharmacological modulation 
of anti-tumor immunity induced by oncolytic viruses. Front Oncol, 2014. 
4: p. 191. 
  
 
73 
54. Sze, D.Y., T.R. Reid, and S.C. Rose, Oncolytic virotherapy. J Vasc 
Interv Radiol, 2013. 24(8): p. 1115-22. 
55. Alemany, R. and M. Cascallo, Oncolytic viruses from the perspective of 
the immune system. Future Microbiol, 2009. 4(5): p. 527-36. 
56. Iankov, I.D., et al., Infected cell carriers: a new strategy for systemic 
delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther, 
2007. 15(1): p. 114-22. 
57. Senzer, N.N., et al., Phase II clinical trial of a granulocyte-macrophage 
colony-stimulating factor-encoding, second-generation oncolytic 
herpesvirus in patients with unresectable metastatic melanoma. J Clin 
Oncol, 2009. 27(34): p. 5763-71. 
58. UM Lauer 1, M.Z., J Sturm 1, S Berchtold 1, U Koppenhöfer 1, M Bitzer 
1, NP Malek 1, J Glatzle 2, A Königsrainer 2, R Möhle 3, F Fend 4, C 
Pfannenberg 5, T Auth 6, T Yu 7, AA Szalay 6, 7, 8, Virotherapy of 
peritoneal carcinomatosis. Z Gastroenterol, 2013. 
59. Russell, S.J., K.W. Peng, and J.C. Bell, Oncolytic virotherapy. Nat 
Biotechnol, 2012. 30(7): p. 658-70. 
60. Fisher, K.D. and L.W. Seymour, HPMA copolymers for masking and 
retargeting of therapeutic viruses. Adv Drug Deliv Rev, 2010. 62(2): p. 
240-5. 
61. Eto, Y., et al., Development of PEGylated adenovirus vector with 
targeting ligand. Int J Pharm, 2008. 354(1-2): p. 3-8. 
62. Duncan, R., Polymer conjugates as anticancer nanomedicines. Nat Rev 
Cancer, 2006. 6(9): p. 688-701. 
63. Croyle, M.A., et al., PEGylation of a vesicular stomatitis virus G 
pseudotyped lentivirus vector prevents inactivation in serum. J Virol, 
2004. 78(2): p. 912-21. 
64. Doronin, K., et al., Chemical modification with high molecular weight 
polyethylene glycol reduces transduction of hepatocytes and increases 
efficacy of intravenously delivered oncolytic adenovirus. Hum Gene 
Ther, 2009. 20(9): p. 975-88. 
65. Power, A.T. and J.C. Bell, Taming the Trojan horse: optimizing dynamic 
carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther, 
2008. 15(10): p. 772-9. 
66. Ilett, E.J., et al., Dendritic cells and T cells deliver oncolytic reovirus for 
tumour killing despite pre-existing anti-viral immunity. Gene Ther, 2009. 
16(5): p. 689-99. 
67. Mader, E.K., et al., Mesenchymal stem cell carriers protect oncolytic 
measles viruses from antibody neutralization in an orthotopic ovarian 
cancer therapy model. Clin Cancer Res, 2009. 15(23): p. 7246-55. 
68. Ilett, E.J., et al., Internalization of oncolytic reovirus by human dendritic 
cell carriers protects the virus from neutralization. Clin Cancer Res, 
2011. 17(9): p. 2767-76. 
69. Qiao, J., et al., Loading of oncolytic vesicular stomatitis virus onto 
antigen-specific T cells enhances the efficacy of adoptive T-cell therapy 
of tumors. Gene Ther, 2008. 15(8): p. 604-16. 
70. WHO, WHO Measles Fact Sheet, in -. 2016, WHO: www.who.int. 
  
 
74 
71. Holzmann, H., et al., Eradication of measles: remaining challenges. Med 
Microbiol Immunol, 2016. 205(3): p. 201-8. 
72. Griffin, D.E. and M.M. Oldstone, Measles. Pathogenesis and control. 
Introduction. Curr Top Microbiol Immunol, 2009. 330: p. 1. 
73. http://www.ictvonline.org/virusTaxonomy.asp?taxnode_id=20151044. 
ICTV: International Committee on Taxonomy of Viruses 2015. 
74. Brandler, S. and F. Tangy, Vaccines in development against West Nile 
virus. Viruses, 2013. 5(10): p. 2384-409. 
75. Yanagi, Y., M. Takeda, and S. Ohno, Measles virus: cellular receptors, 
tropism and pathogenesis. J Gen Virol, 2006. 87(Pt 10): p. 2767-79. 
76. Enders, J.F., et al., Measles virus: a summary of experiments concerned 
with isolation, properties, and behavior. Am J Public Health Nations 
Health, 1957. 47(3): p. 275-82. 
77. Msaouel, P., et al., Attenuated oncolytic measles virus strains as cancer 
therapeutics. Curr Pharm Biotechnol, 2012. 13(9): p. 1732-41. 
78. Noll, M., et al., Primary resistance phenomena to oncolytic measles 
vaccine viruses. Int J Oncol, 2013. 43(1): p. 103-12. 
79. Galanis, E., et al., Oncolytic measles virus expressing the sodium iodide 
symporter to treat drug-resistant ovarian cancer. Cancer Res, 2015. 
75(1): p. 22-30. 
80. Kilstrup, M., et al., Genetic evidence for a repressor of synthesis of 
cytosine deaminase and purine biosynthesis enzymes in Escherichia 
coli. J Bacteriol, 1989. 171(4): p. 2124-7. 
81. Mullen, C.A., M. Kilstrup, and R.M. Blaese, Transfer of the bacterial 
gene for cytosine deaminase to mammalian cells confers lethal 
sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl 
Acad Sci U S A, 1992. 89(1): p. 33-7. 
82. Yurttas, C., et al., Pulsed versus continuous application of the prodrug 5-
fluorocytosine to enhance the oncolytic effectiveness of a measles 
vaccine virus armed with a suicide gene. Hum Gene Ther Clin Dev, 
2014. 25(2): p. 85-96. 
83. Melcher, A., et al., Thunder and lightning: immunotherapy and oncolytic 
viruses collide. Mol Ther, 2011. 19(6): p. 1008-16. 
84. Heo, J., et al., Randomized dose-finding clinical trial of oncolytic 
immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med, 2013. 
19(3): p. 329-36. 
85. Bossow, S., et al., Armed and targeted measles virus for 
chemovirotherapy of pancreatic cancer. Cancer Gene Ther, 2011. 18(8): 
p. 598-608. 
86. Skehan, P., et al., New colorimetric cytotoxicity assay for anticancer-
drug screening. J Natl Cancer Inst, 1990. 82(13): p. 1107-12. 
87. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J Immunol Methods, 
1983. 65(1-2): p. 55-63. 
88. May, V., et al., Chemovirotherapy for pancreatic cancer: Gemcitabine 
plus oncolytic measles vaccine virus. OL, 2019. 18(5): p. 5534-5542. 
  
 
75 
89. Wennier, S.T., et al., Myxoma virus sensitizes cancer cells to 
gemcitabine and is an effective oncolytic virotherapeutic in models of 
disseminated pancreatic cancer. Mol Ther, 2012. 20(4): p. 759-68. 
90. Braig, M. and C.A. Schmitt, Oncogene-induced senescence: putting the 
brakes on tumor development. Cancer Res, 2006. 66(6): p. 2881-4. 
91. Stepanenko, A.A. and V.V. Dmitrenko, Pitfalls of the MTT assay: Direct 
and off-target effects of inhibitors can result in over/underestimation of 
cell viability. Gene, 2015. 574(2): p. 193-203. 
92. Krizhanovsky, V., et al., Implications of cellular senescence in tissue 
damage response, tumor suppression, and stem cell biology. Cold 
Spring Harb Symp Quant Biol, 2008. 73: p. 513-22. 
93. Focaccetti, C., et al., Effects of 5-fluorouracil on morphology, cell cycle, 
proliferation, apoptosis, autophagy and ROS production in endothelial 
cells and cardiomyocytes. PLoS One, 2015. 10(2): p. e0115686. 
94. Gradiz, R., et al., MIA PaCa-2 and PANC-1 - pancreas ductal 
adenocarcinoma cell lines with neuroendocrine differentiation and 
somatostatin receptors. Sci Rep, 2016. 6: p. 21648. 
95. Skelding, K.A., R.D. Barry, and D.R. Shafren, Enhanced oncolysis 
mediated by Coxsackievirus A21 in combination with doxorubicin 
hydrochloride. Invest New Drugs, 2012. 30(2): p. 568-81. 
96. Angelova, A.L., et al., Improvement of gemcitabine-based therapy of 
pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin 
Cancer Res, 2009. 15(2): p. 511-9. 
97. Tedcastle, A., et al., Virotherapy--cancer targeted pharmacology. Drug 
Discov Today, 2012. 17(5-6): p. 215-20. 
98. Eisenberg, D.P., et al., 5-fluorouracil and gemcitabine potentiate the 
efficacy of oncolytic herpes viral gene therapy in the treatment of 
pancreatic cancer. J Gastrointest Surg, 2005. 9(8): p. 1068-77; 
discussion 1077-9. 
99. Hertel, L.W., et al., Evaluation of the antitumor activity of gemcitabine 
(2',2'-difluoro-2'-deoxycytidine). Cancer Res, 1990. 50(14): p. 4417-22. 
100. DeLong, D.C., Hertel, L.W., Tang, J., Kroin, J. S., Wilson, J. D., Terry,J., 
Lavender, J.F. , Antiviral activity of 2',2'-difluorodeoxycytidine. Abstracts  
of Meeting  of American  Society of Microbiology,  March  24-
28,Washington,  DC, 1986., 1986. 
101. Mezhir, J.J., et al., Ionizing radiation activates late herpes simplex virus 
1 promoters via the p38 pathway in tumors treated with oncolytic viruses. 
Cancer Res, 2005. 65(20): p. 9479-84. 
102. Chahlavi, A., et al., Replication-competent herpes simplex virus vector 
G207 and cisplatin combination therapy for head and neck squamous 
cell carcinoma. Neoplasia, 1999. 1(2): p. 162-9. 
103. Wang, Y., et al., Efficacy and safety of gemcitabine plus erlotinib for 
locally advanced or metastatic pancreatic cancer: a systematic review 
and meta-analysis. Drug Des Devel Ther, 2016. 10: p. 1961-72. 
104. Ruf, B., et al., Combination of the oral histone deacetylase inhibitor 
resminostat with oncolytic measles vaccine virus as a new option for epi-
  
 
76 
virotherapeutic treatment of hepatocellular carcinoma. Mol Ther 
Oncolytics, 2015. 2: p. 15019. 
105. Ellerhoff, T.P., et al., Novel epi-virotherapeutic treatment of pancreatic 
cancer combining the oral histone deacetylase inhibitor resminostat with 
oncolytic measles vaccine virus. Int J Oncol, 2016. 49(5): p. 1931-1944. 
106. Igase, M., et al., Combination Therapy with Reovirus and ATM Inhibitor 
Enhances Cell Death and Virus Replication in Canine Melanoma. Mol 
Ther Oncolytics, 2019. 15: p. 49-59. 
107. Rajaraman, S., et al., Measles Virus-Based Treatments Trigger a Pro-
inflammatory Cascade and a Distinctive Immunopeptidome in 
Glioblastoma. Mol Ther Oncolytics, 2019. 12: p. 147-161. 
108. Ruf, B. and U.M. Lauer, Assessment of current virotherapeutic 
application schemes: "hit hard and early" versus "killing softly"? Mol Ther 
Oncolytics, 2015. 2: p. 15018. 
109. Wang, H., et al., Optical detection and virotherapy of live metastatic 
tumor cells in body fluids with vaccinia strains. PLoS One, 2013. 8(9): p. 
e71105. 
110. Cho, E., et al., Preclinical safety evaluation of hepatic arterial infusion of 
oncolytic poxvirus. Drug Des Devel Ther, 2018. 12: p. 2467-2474. 
111. Berchtold, S., et al., Innate immune defense defines susceptibility of 
sarcoma cells to measles vaccine virus-based oncolysis. J Virol, 2013. 
87(6): p. 3484-501. 
112. Chiocca, E.A. and S.D. Rabkin, Oncolytic viruses and their application to 
cancer immunotherapy. Cancer Immunol Res, 2014. 2(4): p. 295-300. 
113. Dietz, L. and C.E. Engeland, Immunomodulation in Oncolytic Measles 
Virotherapy. Methods Mol Biol, 2020. 2058: p. 111-126. 
114. Peng, K.W., et al., Using clinically approved cyclophosphamide 
regimens to control the humoral immune response to oncolytic viruses. 
Gene Ther, 2013. 20(3): p. 255-61. 
115. Liu, C., S.J. Russell, and K.W. Peng, Systemic therapy of disseminated 
myeloma in passively immunized mice using measles virus-infected cell 
carriers. Mol Ther, 2010. 18(6): p. 1155-64. 
116. Melzer, M.K., et al., Enhanced Safety and Efficacy of Oncolytic VSV 
Therapy by Combination with T Cell Receptor Transgenic T Cells as 
Carriers. Mol Ther Oncolytics, 2019. 12: p. 26-40. 
117. Andtbacka, R.H.I., et al., Final analyses of OPTiM: a randomized phase 
III trial of talimogene laherparepvec versus granulocyte-macrophage 
colony-stimulating factor in unresectable stage III-IV melanoma. J 
Immunother Cancer, 2019. 7(1): p. 145. 
118. Harrington, K.J., et al., Efficacy and safety of talimogene laherparepvec 
versus granulocyte-macrophage colony-stimulating factor in patients with 
stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM 
trial. Onco Targets Ther, 2016. 9: p. 7081-7093. 
119. Haanen, J.B. and C. Robert, Immune Checkpoint Inhibitors. Prog Tumor 
Res, 2015. 42: p. 55-66. 
120. Pardoll, D.M., The blockade of immune checkpoints in cancer 
immunotherapy. Nat Rev Cancer, 2012. 12(4): p. 252-64. 
  
 
77 
121. Engeland, C.E., et al., CTLA-4 and PD-L1 checkpoint blockade 
enhances oncolytic measles virus therapy. Mol Ther, 2014. 22(11): p. 
1949-59. 
122. Dias, J.D., et al., Targeted cancer immunotherapy with oncolytic 
adenovirus coding for a fully human monoclonal antibody specific for 
CTLA-4. Gene Ther, 2012. 19(10): p. 988-98. 
123. Mullins-Dansereau, V., et al., Pre-surgical oncolytic virotherapy improves 
breast cancer outcomes. Oncoimmunology, 2019. 8(11): p. e1655363. 
124. Singh, H.M., G. Ungerechts, and A.M. Tsimberidou, Gene and cell 
therapy for pancreatic cancer. Expert Opin Biol Ther, 2015. 15(4): p. 
505-16. 
125. Zamarin, D., et al., Localized oncolytic virotherapy overcomes systemic 
tumor resistance to immune checkpoint blockade immunotherapy. Sci 
Transl Med, 2014. 6(226): p. 226ra32. 
 
 
 
 
 
 
 
 
 
  
 
78 
Erklärung zum Eigenanteil der Dissertationsschrift 
 
Die Arbeit wurde zunächst in der Medizinischen Universitätsklinik, Abteilung für 
Innere Medizin I, begonnen und dann später in der Abteilung für Innere Medizin 
VIII unter Betreuung von Herrn Prof. Dr. U.M. Lauer durchgeführt. 
Die Konzeption der Studie erfolgte durch Herrn Prof. Dr. U.M. Lauer in 
Zusammenarbeit mit Frau Dr. S. Berchtold (wiss. Mitarbeiterin und Labor-
leiterin). 
Sämtliche Versuche wurden (nach Einarbeitung durch Frau I. Smirnow, MTA) 
von mir eigenständig durchgeführt. Die Einarbeitung in die Methodik des SA-β-
Gal assay sowie die Mitbetreuung erfolgte von Drs. S. Venturelli, A. Berger und 
Dipl. Biochem. C. Leischner. 
Die statistische Auswertung erfolgte in Zusammenarbeit mit den Drs. S. 
Venturelli und M. Burkard 
Ich versichere, das Manuskript selbständig (nach Anleitung durch Frau Dr. S. 
Berchtold und Prof. U.M. Lauer) verfasst zu haben und keine weiteren als die 
von mir angegebenen Quellen verwendet zu haben. 
Ergebnisse der Dissertationsschrift wurde im September 2019 online und im 
November 2019 gedruckt im Journal „Oncology Letters“ des Spandidos-
Verlages unter dem Titel „Chemovirotherapy for pancreatic cancer: 
Gemcitabine plus oncolytic measles vaccine virus”, doi: 10.3892/ol.2019.10901 
veröffentlicht. Die Publikation ist als vollständiger Text online einzusehen. 
Jegliche in der Doktorarbeit verwendete Abbildungen und Texte sind 
dementsprechend in der Beschreibung oder als Direktzitat kenntlich gemacht. 
Weitere Präsentationen der Ergebnisse der Doktorarbeit fanden bei folgenden 
Kongressen statt: 
 
 
• Posterpräsentation beim AEK-Kongress in Heidelberg 27.02.-01.03.2019 
unter dem Titel „Chemovirotherapy for Pancreatic Cancer: Gemcitabine 
plus Oncolytic Measles Vaccine Virus” 
 
• Kurzvortrag auf dem Kongress 2014 der DGVS am 19.09.2014 in 
  
 
79 
Leipzig unter dem Titel: “Combination therapy with chemotherapeutics 
and oncolytic measles vaccine viruses as a new option for the treatment 
of pancreatic cancer“ 
 
• Posterpräsentation beim Forschungskolloquium der Medizinischen 
Fakultät des Universitätsklinikum Tübingen im Rahmen des IZKF-
Promotionskollegs am 08.10.2013 unter dem Titel „Combination Therapy 
with Cytostatics and Oncolytic Measles Vaccine Viruses as a new Option 
for the Treatment of Pancreatic Cancer” (vorläufige Ergebnisse) 
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